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ABSTRACT 
 
 
 Glioma is a brain tumor that arises from glial cells or glial progenitor cells, and 
represents 80% of malignant brain tumor incidence in the United States.  Glioblastoma 
multiforme (GBM) is the most aggressive primary brain tumor malignancy with fewer 
than 8% of patients with GBM surviving for 3 years. Over the past 10 years, despite 
improvement in diagnosis and therapies for cancer, the survival rate for high-grade 
glioma patients remains unchanged. The main focus of this dissertation is to investigate 
two therapeutic agents that are related to increase tumor resistance or increase secondary 
tumor incidence, which might play a role in poor prognosis and outcome for glioma. 
There are several studies, which show that corticosteroid treatment increases tumor 
resistance to chemo- and radiotherapy. Corticosteroids are mainstay drugs for managing 
peritumoral edema. Therefore, we investigated the effect of corticosteroids in a PDGF 
driven glioma mouse model. We found that corticosteroid treatment decreases tumor cell 
proliferation without inducing cell death as shown by a significant decrease in PCNA and 
Ki67 but not in cleaved caspase-3 staining. Decreased tumor cell growth could 
compromise the responsiveness of tumor cells to chemotherapy and/or radio-therapy, 
because cancer therapeutics often target rapidly growing cells. In addition, we found that 
corticosteroids decrease tumor-associated microglial cells proliferation. Furthermore, in 
vitro and in vivo studies revealed a shift in microglial cells to less pro-tumor phenotype as 
evidenced by decreasing MMP9 and IL-1ra expression. However, we did not find an 
association between the decrease in tumor proliferation and the shift in microglia 
phenotype. In addition, the use of thiopurine drugs in leukemia treatment was associated 
with the development of secondary cancers including glioma. Therefore, we investigated 
the cytotoxic effects of thiopurine drugs in primary astroglial cultures. Thiopurine drugs 
are commonly used to treat cancer, autoimmune disorders, and transplantation. However, 
thiopurines and their metabolites can be inactivated by the thiopurine methyltransferase 
(TPMT) enzyme. We found that a low TPMT phenotype predicted significantly higher 
sensitivity to the cytotoxic action of thiopurines than did a high TPMT phenotype. 
Thiopurines induced significantly more cell death and DNA damage in primary 
astrocytes and human glioma cells with low TPMT versus high TPMT. It is possible that 
the DNA damage caused by low TPMT function can ultimately contribute to 
transformative events over time. Finally, we assessed the anticancer activity of 2 classes 
of novel small molecules; tetrahydroisoquinoline (THIQ) and chromenes. These 
molecules were screened in vitro to find the most potent anticancer derivatives that 
exhibited the least toxicity on normal stromal cells. EDL-360 (5-10 μM) and SP-6-27 
(IC50 = 7-21 nM) were the most potent analogs of THIQ and chromene in glioma cells, 
respectively, and low cytotoxic action was observed in normal astrocytes. Furthermore, 
theses compounds induced a partial regression in glioma tumor engraftment. 
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CHAPTER 1.    INTRODUCTION 
 
 
Glioma arises from glial cells or glial progenitor cells, and is the most frequent 
type of brain tumor [1]. Glial cells, which include astrocytes, oligodendrocytes and 
ependymal cells, support and maintain normal brain homeostasis.  Each of these glial cell 
types can give rise to a distinctive type of cancer. Glioblastoma multiforme (GBM), 
however, is the most aggressive primary brain tumor malignancy [1,2]. Despite the fact 
that GBM is infrequent, it is clinically significant because more than 60% of the patients 
die within 1 year from diagnosis [2]. One of the major concerns is glioma resistance to 
chemotherapy and radiotherapy, which enables tumor cells to repopulate, and thus 
causing relapse in 50% of the patients. Recurring tumors are usually more aggressive and 
resistant to therapy [3]. In the past 10 years, the survival rate remains substantially low 
for glioma patients. The basic hypothesis to be examined in this thesis is that therapy 
related resistance and toxicity play a role in the poor prognosis and outcome in glioma. 
The objectives of this study are: 
 
1- To investigate the effects of corticosteroids (anti-edema) in glioma. 
2- To investigate thiopurine (anti-leukemia) induced toxicity in astrocytes with 
different TPMT phenotypes. 
3- To characterize novel small molecules that exhibit anti-glioma activity. 
 
 
Glioma Epidemiology 
 
The global incidence of malignant brain tumors is estimated to be approximately 
3 in 100,000 per year, with a higher rate in the developed countries compared to the 
developing countries [4,5]. According to the Central Brain Tumor Registry of the United 
States (CBTRUS) report, an incidence of 109,695 malignant brain tumors were reported 
between 2005-2009 [2]. Gliomas represent 29% of primary brain tumors and 80% of 
malignant brain tumors. Three-year relative survival rate of the low-grade diffuse 
astrocytoma is 55%, while it is less than 8% of GBM patients. Of note, the mortality rate 
increases with age. For example, a 5 year relative survival for GBM patients in the fourth 
decade of their life is approximately 17%, but for the patients in the seventh decade of 
their life is 1.6% [2]. In addition, being a white male increases the risk for developing 
malignant glioma. However, females are at higher risk for non-malignant brain tumors 
[5]. 
 
 
Clinical Presentation 
 
At clinical presentation, the most frequent symptoms for newly diagnosed and 
relapsed glioma patients are headache, behavioral changes, hemiparesis, seizures, nausea 
and vomiting [6]. Typically, the headache is worse in the morning but gradually 
alleviates during the day. Nevertheless, brain tumor patients often suffer from changes in 
personality and cognitive abilities [3]. One of the major concerns is the development of 
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neurological symptoms and irreversible neurological damage due to the size of these 
tumors and their critical location in the brain [3]. In addition to these neurological 
defects, GBM patients usually suffer from cerebral edema, which is characterized by an 
increased brain volume due to leakage of the plasma into brain parenchyma (5). 
Peritumoral edema is considered to be a significant cause of death because it leads to 
increased intracranial pressure (ICP) [7]. Corticosteroids are often employed to alleviate 
these neurological symptoms [8], but have been corticosteroid treatment has been 
associated with various adverse effects that interfere with the quality of life of the patient. 
The adverse effects include behavioral changes, insomnia, myopathy, hyperglycemia, 
weight gain, peptic ulcer [9]. Moreover, withdrawal of steroid therapy is also associated 
with severe side effects including steroid withdrawal syndrome (i.e. headache and 
lethargy) and adrenal insufficiency due to a lack of the production of endogenous 
corticosteroids [9,10]. The effect of corticosteroids on glioma disease will be discussed in 
chapter 2. 
 
 
Diagnosis 
 
Brain tumor diagnosis starts with non-invasive anatomic imaging techniques such 
as computerized tomography (CT). X-ray CT scans provide volume imaging by a 
simultaneous movement of the X-ray source and the film from one position to another. 
Consequently, tumor location and the associated structure can be identified. The problem 
with the CT scans, however, is that the images are quite blurry [6,11]. Alternatively, 
magnetic resonance imaging (MRI) provides a more sensitive detection of small size 
tumors, location and other abnormal tissue structure. Moreover, it is considered to be safe 
since it utilizes radio-frequency waves (i.e. non-radioactive). However, it is a more 
expensive approach than CT scans [12]. Proton Magnetic Resonance Spectroscopic 
Imaging (1H-MRSI) is another advanced imaging tool that provides more accurate 
information about the location as well as the cellular and metabolic activity of the tumor 
[13,14]. On T2-weighted MRI, low grade astrocytomas appear as hyperintense (bright) 
area with defined borders [6]. Owing to the infiltrative nature of high grade gliomas, they 
exhibit irregular contrast enhancement and involve both hemispheres [6]. Although MRI 
imaging is a valuable diagnostic tool, the final tumor identification and grading is not 
confirmed until histopathological analysis of a patients’ biopsy is performed [3]. 
 
 
Histopathological and Molecular Classification 
 
 
Histopathological Classification 
 
According to the World Health Organization (WHO), gliomas can be 
histologically classified into several categories based on their morphological resemblance 
to glial cells. Within each category, the tumors are further graded based on malignancy. 
The grades are designated by numbers range from “I”, for the least malignant tumors, to 
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“IV”, for most the malignant tumors [15]. For example, astroglial tumors closely 
resemble astrocytes whereas oligodendroglial tumors resemble oligodendrocytes. 
 
Low-grade piloctic astrocytomas typically arise in the hypothalamic region and 
usually they are not accompanied with cerebral edema [6,15]. However, high-grade 
astrocytomas, including anaplastic astrocytoma and GBM (Figure 1-1), arise in the 
cerebral cortex. GBMs are highly heterogeneous and complex in nature, and their 
incidence peaks in the fifth and the sixth decade of life [1,6]. Necrotic regions, 
hemorrhage, pleomorphic nuclei and vascular proliferation are characteristic of GBM. In 
addition, GBM highly infiltrates normal tissue forming the secondary structures of 
Scherer, in which tumor cells surround blood vessels, neurons and subpial zone in the 
cereberal cortex [16]. 
 
 
Molecular Classification 
 
Histologically similar tumors can vary significantly on a molecular basis. The 
Cancer Genome Atlas (TCGA) dataset has been used to classify GBM into 4 molecular 
subclasses: classical, mesenchymal, proneural, and neural [17,18]. The frequently altered 
oncogenes and tumor suppressor genes in glioma are summarized in Figure 1-2 [19]. The 
Epidermal growth factor receptor (EGFR) overexpression is frequently altered in the 
"Classical" subtype of GBM. Moreover, combined deletion of INK4a/ARF and EGFR 
amplification are observed in 94% of this subtype. Neurofibromin 1 (NF1) is a tumor 
suppressor gene that is mutated in 18% of GBM cases and 53% of "Mesenchymal" 
molecular subtype of glioma [18,20]. However, proneural subclass of GBM is 
characterized by frequent amplification in platelet derived growth factor receptor 
(PDGFR) (11%) and point mutations in isocitrate dehydrogenase 1 (IDH1) (30%). In 
addition, TP53 and PTEN are altered in 54% and 16% of proneural subclass cases [18]. 
Finally, neural subclass is characterized by neural markers expression; NEFL, GABRA1, 
SYT1, and SLC12A5. EGFR is also frequently amplified in this subclass but to a lesser 
extent compared to the classical subtype.  
 
 
Glioma Treatment 
 
 
Ionizing Radiation 
 
The heterogeneous nature of GBM plays a prominent role in therapeutic 
resistance [1]. The treatment of brain tumors involves both local and systemic therapeutic 
approaches. Typically tumor resection is employed to remove the majority of the tumor 
[1,3]. However, complete tumor resection is very challenging due to the diffuse 
infiltrative nature of these tumors into normal brain parenchyma [21]. As a result, these 
tumors can repopulate and increase in size significantly after surgery [3]. Cranial 
irradiation often follows surgical resection. The radiotherapy can alleviate the 
neurological symptoms and seizures in glioma patients [3]. However, radiotherapy is not  
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Figure 1-1. Histological and molecular classification of gliomas. 
 
According to the WHO gliomas can be histologically classified into several groups 
depending on the glial cell of origin. Recent studies further identified 4 molecular 
subclasses of GBM. 
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Figure 1-2. Molecular pathways frequently altered in glioma. 
 
Binding of EGF/PDGF growth factors to the EGFR/PDGFR tyrosine kinase receptor 
leads to the activation of RAS/RAF and RAS/PI3K survival pathways. Tumor suppressor 
genes NF1 and PTEN inhibit the activity of RAS and PI3K oncogenes, respectively. 
Ink4a and ARF tumor suppressor genes are frequently mutated in glioma and their loss 
leads to silencing RB and p53 respectively. Adapted with permission from Patil SA, 
Hosni-Ahmed A, Jones TS, Patil R, Pfeffer LM, et al. (2013) Novel approaches to glioma 
drug design and drug screening. Expert Opin Drug Discov 8: 1135-1151. 
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recommended for elderly patients (> 70 years) because the side effects of irradiation are 
usually more severe in the elderly. Typically, the radiotherapy regimen is 54-60 Gy given 
in 30 fractions during 6 weeks of treatment [3]. However, it is not recommended to delay 
radiotherapy for GBM patients from the time of presentation as it might decrease the 
overall patient survival rate [22]. 
 
 
Chemotherapy 
 
 Systemic chemotherapy is another treatment option for GBM patients. In 1999, 
the Food and Drug Administration (FDA) approved Temozolomide (TMZ; Temodar®) 
for treating refractory anaplastic astrocytoma, and in 2005 TMZ was approved for GBM 
treatment. Concurrent treatment of 75 mg of TMZ /m2/day and irradiation followed by 
~150 mg of TMZ /m2/day prolonged the median survival rate to 14.6 months versus 12.1 
months for radiotherapy alone [23,24]. This adjuvant TMZ therapy was given 5 
days/week for 1 year (28 day cycle) [23]. Of note, the methylation status of 
O6-methylguanine-DNA methyltransferase (MGMT) promoters is a good predictor of the 
sensitivity to TMZ therapy. In particular, unmethylated active MGMT enzyme 
compromises TMZ genotoxicity by removing the alkyl group from the DNA [25]. 
Therefore, glioma patients with unmethylated MGMT promoter are more resistant to 
TMZ compared to patients harboring methylated MGMT. Finally, Bevacizumab 
(Avastin®) is another chemotherapeutic agent that was recently approved for recurrent 
GBM [24]. 
 
 
Corticosteroids in Managing Peritumoral Edema 
 
Despite the fact that corticosteroids are not directly employed as anti-neoplastic 
drugs, they are essential component in managing peritumoral edema. Glucocorticoids are 
stress hormones that control a wide variety of biological processes such as inflammation, 
metabolism and behavior [26]. Dexamethasone (Dex), a synthetic corticosteroid, is the 
most favored corticosteroid drug used by clinicians, whereas the second preferred drug is 
methylprednisolone. This owes to the long biological half-life of Dex and the minimal 
mineralocorticoid effect [27]. The dose employed is quite variable depending on patient 
symptoms. However, the rule of thumb is to use the lowest dose for the shortest period of 
time to avoid the undesirable side effects of corticosteroids. Additionally, gradual 
tapering of Dex is critical to avoid corticosteroid withdrawal syndrome. Corticosteroid 
treatment suppresses the function of the hypothalamic-pituitary-adrenal axis and gradual 
withdrawal allows the recovery of hypothalamic-pituitary-adrenal axis function [9]. 
 
Dex may be used before, during or after radiotherapy, or before or after surgery. 
At the time of clinical presentation, the starting dose of Dex is 16 mg/day for one week. 
However, if the patient is unconscious, 40 mg of Dex is given intravenously [8,9]. After 7 
days, the dose is adjusted based on patient’s symptoms and the extent of tumor resection. 
In case the patient’s symptoms are improving and the tumor has been surgically removed, 
the dose is reduced 50% every 4 days. However, if the symptoms do not improve, the 
 7 
dose can be increased up to 100 mg of Dex daily [8]. In addition, radiotherapy treatment 
can cause a slight increase in brain volume, which might require Dex treatment. 
 
 
Corticosteroids  
 
 
Mechanism of Action 
 
Corticosteroids achieve their anti-inflammatory effect by acting as a 
trans-activators or trans-repressors of gene transcription. They are lipophilic substances 
that can pass through the plasma cell membrane by simple diffusion. Once inside the cell, 
they bind to glucocorticoid receptors (GR) in the cytoplasm [28]. The hormone-receptor 
homodimer complex releases the 90 kDa heat-shock protein that allows the complex to 
translocate into the nucleus [29]. Binding of the complex to the glucocorticoid responsive 
elements (GRE) on the DNA drives the expression of anti-inflammatory cytokines such 
as interleukin-10 (IL-10) and interleukin 1 receptor antagonist (IL-1ra) [30]. However, 
the glucocorticoid-receptor complex can act as a trans-repressor as well by suppressing 
the expression of pro-inflammatory cytokines. This activity is achieved by interfering 
with and inhibiting transcription factors, such as NF-κB and activating protein 1 (AP-1), 
which drives the expression of pro-inflammatory cytokines [31,32]. Recently, 
glucocorticoids have also been shown to play a role in chromatin remodeling and hence 
RNA transcription [33]. GR can bind to and inhibit the function of CREB binding protein 
(CBP). CBP causes histone acetylation that allows DNA unwinding and hence makes 
DNA more accessible for transcription machinery. Additionally, GR recruits histone 
deacetylase-2 (HDAC2), therefore allowing the compaction of DNA and suppression of 
gene expression [33,34]. 
 
 
Possible Effects of Corticosteroids on Glioma 
 
Dex is intensively used in the clinic for alleviating peritumoral edema. However, 
the exact mechanism of how Dex alleviates cerebral edema is unknown. Furthermore, the 
effect of dexamethasone on tumor cells is controversial. For instance, some studies 
suggested that it has an anti-proliferative effect in vivo [35]. While other studies have 
shown that dexamethasone stimulates cell growth at low concentrations and inhibits cell 
growth at high concentration [36]. This is particularly important because cancer 
therapeutics often target rapidly growing cells. Therefore, Dex might compromise the 
responsiveness of tumor cells to DNA damaging agents such as chemo and/or 
radio-therapies by slowing down tumor cell replication. Indeed, the use of corticosteroid 
has shown to increase tumor’s radioresistance, however, this effect seems to be cell type 
dependent [37]. Perhaps the upregulation of steroid receptors following ionizing radiation 
therapy is the mechanism responsible for Dex-induced radioresistance [38]. Such 
findings highlight the desperate need to understand the specific effect of Dex on tumor 
cells especially for patients undergoing concomitant chemotherapy or radiotherapy 
concurrently with corticosteroids. In our studies, we investigated the effect of Dex on 
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glioma cell proliferation and death using a genetically engineered mouse model of 
glioma. However, Dex is not the only drug being associated with severe adverse effect 
and toxicity. For example the development of secondary tumors in patients has been 
associated with thiopurine drug treatment. 
 
 
Thiopurine Drugs 
 
 
Thiopurine Metabolism  
 
Thiopurine drugs (i.e. thioguanine, mercaptopurine, and azathioprine) are 
commonly used in the treatment of cancer, autoimmune disorders, and transplantation. 
These agents are pro-drugs that require intracellular conversion to the cytotoxic 
thioguanine nucleotide (TGN) metabolites by a series of enzymatic reactions to exert 
their effects [39].  The primary mechanism of thiopurine cytotoxicity is believed to be 
through the incorporation of TGNs into DNA (DNA-TG) followed by methylation of the 
DNA-TG bases and subsequent processing by the mismatch repair system [40]. 
Additionally, inhibition of de novo purine synthesis by methylthioinosine monophosphate 
(meTIMP) is believed to play some role in how thiopurine drugs work; however 
thioguanine bypasses the conversion to meTIMP. Alternatively, thiopurines and their 
metabolites can be inactivated by the thiopurine methyltransferase (TPMT) enzyme.  
 
 
Thiopurine Methyltransferase 
 
TPMT is a cytoplasmic enzyme that catalyzes the S-methylation of aromatic and 
heterocyclic compounds using S-adenosyl-L-methionine as a methyl donor. However, the 
endogenous substrate for TPMT has not yet been identified [41]. Indeed, TPMT has been 
studied extensively because of its critical role in the biotransformation of thiopurine 
agents and because of deactivating polymorphisms that can result in low protein activity 
[42,43]. The genetic polymorphism in TPMT results in a trimodal population frequency 
distribution in TPMT protein activity.  Approximately 90% of the population have 
homozygous wild-type TPMT and have high TPMT protein activity; ~10% are 
heterozygous with intermediate protein activity; and less than 1% are homozygous 
mutant for TPMT and have practically no measurable protein activity. TPMT protein 
levels are inversely correlated with the cytotoxic TGN metabolites.  Hence, low TPMT 
protein can lead to high levels of intracellular TGNs and life threatening side effects 
when normal thiopurine doses are administered.  
 
The consequence of low TPMT protein activity is evident in leukemia patient 
populations who receive thiopurines as part of their antileukemic therapy. When these 
patients have a low TPMT phenotype and receive normal doses of thiopurines they are at 
a high risk of life-threatening myelosuppression and secondary cancers [44-46].  
Interestingly, one study found that patients who had a low TPMT phenotype and were 
treated with normal doses of thiopurines concurrently with cranial irradiation as part of 
 9 
their antileukemic therapy were at a higher risk of developing brain cancer as compared 
to patients with normal TPMT [47,48]. However, little is known about TPMT function in 
brain cells. It is plausible that low TPMT function can result in high levels of DNA 
damage without killing the cells and this might lead to cellular transformation. 
 
 
Thiopurines and Incidence of Secondary Brain Tumors 
 
Thiopurine therapy has been associated with cancer development in organ 
transplantation and autoimmune disorder patients (Table 1-1); however, the importance 
of TPMT status is unclear. Unfortunately, with the exception of leukemia patients, most 
patient populations are not evaluated for their TPMT status prior to initiating thiopurine 
therapy.  Since TPMT deficiency is rare across populations, it is difficult to assess the 
importance of TPMT status to thiopurine therapy-associated cancer risk. Here, we 
provide a review of the literature of thiopurine drug therapy-related cancers followed by 
an evaluation of TPMT phenotypes in astroglial cells.   
 
Various types of cancer have been observed in patients who have received 
long-term thiopurine therapy (Table 1-1). A study conducted by Kandiel et al. found that 
inflammatory bowel disease patients treated with AZA have a four-fold increased risk of 
lymphoma [49]. Additionally, there have been several reports suggesting an increased 
risk of malignancy in renal transplant patients who receive azathioprine, which include 
cancers of the skin and brain as well as lymphomas and carcinomas [50-52].  The 
incidence of cutaneous squamous cell carcinoma (SCC) in patients undergoing organ 
transplantation is 100-fold greater than the normal population [53]. The interaction 
between UVA radiation and DNA-TGN causes DNA single and double strand breaks 
possibly due to ROS generation. This in part can explain the high risk of skin cancer in 
organ transplant patients [54].  
 
Thioguanine and mercaptopurine have been used for childhood acute 
lymphoblastic leukemia (ALL) treatment for more than 50 years [55,56]. Several studies 
have reported secondary neoplasms in children treated for ALL including brain cancers, 
lymphomas, carcinomas and sarcomas [48,57-59]. In a protocol conducted at St. Jude 
Children's Research Hospital, almost half of the patients having a low TPMT phenotype 
and who were treated with thiopurines concurrently with cranial irradiation developed 
brain tumors as a late-complication of their anti-leukemic therapy [47]. This raises the 
question of whether TPMT can protect important brain cell populations (i.e. astrocytes) 
from genotoxic events induced by thiopurines. We hypothesize that TPMT deficiency can 
lead to greater DNA damage and cytotoxicity in astroglial cell populations.   
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Table 1-1. Incidences of secondary neoplasm after thiopurine therapy. 
 
Thiopurines Primary disease 
Therapy related 
cancer 
Number of 
patients affected Reference 
AZA Kidney 
transplant 
Nodular malignant 
melanoma 
1 patient in the 
case study 
[51] 
Brain lymphoma 25 patients in the 
case study 
[52] 
Glioblastoma 3 out of 5 patients 
in the case study∏ 
[60] 
Myasthenia 
gravis 
CNS lymphoma 2 patients in the 
case study 
[61] 
Inflammatory 
bowel disease 
Lymphoproliferative 
disorder Ω 
3 patients out of 
5867 
[62] 
Non-Hodgkin’s 
lymphoma 
2 patients out of 
212 
[63] 
Hepatocellular 
carcinoma 
1 patient in the 
case study 
[64] 
Hodgkin’s 
lymphoma 
1 patients out of 1 [65] 
MP Inflammatory 
bowel disease 
Hodgkin’s 
lymphoma 
1 patient out of 
5867 
[62] 
Lymphoma 5 patients out of 5 [65] 
ALL Brain tumor 7 out of 188 
patients† 
[47] 
MDS 8 out of 1225 
patients 
[66] 
 
PTLD 1 out of 1225 
patients 
[66] 
 
Oral carcinoma 1 out of 1225 
patients 
[66] 
 
Oral carcinoma 1 out of 1225 
patients 
[66] 
 
Thyroid carcinoma 1 out of 1225 
patients 
[66] 
 
PNET 1 out of 1225 
patients 
[66] 
 
Intracranial 
neoplasms ¶ 
1 out of 2 patients 
in the case study æ 
[67] 
 
Abbreviations: 
 
ALL, acute lymphoblastic leukemia; AML, actute myloid leukemia; AZA, azathiopurine; 
MP, mercaptopurine; MDS, Myelodysplasic syndrome PNET, primitive neuroectodermal 
tumor in central nervous system; PTLD, post-transplantation lymphoproliferative disease 
∏ These three patients received azathiopurine 
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Table 1-1. Continued. 
 
Ω Lymphoproliferative disorder (LD) includes Anaplastic large cell LD, immunoblastic  
B-cell lymphoma and B follicular lymphoma 
† The incidence of secondary brain tumors in TPMT deficient patients is 42.9% while in 
TPMT proficient patients is 8.3% 
¶ Neuroectodermal tumor with astrocytic and neuroblastic nature. 
æ This patient received mercaptopurine 
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CHAPTER 2.    THE EFFECTS OF CORTICOSTEROIDS ON GLIOMA AND 
MICROGLIAL CELLS 
 
 
Introduction 
 
 
Glioblastoma Multiforme 
 
GBM is one of the most devastating and aggressive types of brain cancer. 
According to the CBTRUS report, an incidence of 109,695 malignant brain tumors was 
reported between 2005-2009 [2,68]. Despite the therapeutic advancement, the estimated 
overall survival is 3 years for approximately only 7% of the patients [2]. The typical 
treatment strategy starts with tumor resection to remove the bulk of the tumor. However, 
complete tumor resection is very challenging due to the diffuse infiltration nature of the 
tumor into normal brain parenchyma [21]. In addition, tumor recurrence is inevitable for 
glioma patients, partially because of failure to remove all tumor cells. Surgical resection 
of the tumor is then followed by aggressive radio-therapy and chemo-therapy 
(Temozolomide) [69-71]. 
 
 
Tumor Associated Edema 
 
High-grade gliomas such as GBM are usually associated with cerebral edema, 
which is characterized by an increase in the brain volume due to leakage of the plasma 
into brain parenchyma (5). Peritumoral edema is considered to be a significant cause of 
death because it leads to increased intracranial pressure (ICP) [7]. At clinical 
presentation, headache, nausea, vomiting and impaired eye movement are the typical 
symptoms, which substantially impair the quality of life of brain tumor patients [6,9]. 
Since the introduction of Dex, a synthetic glucocorticoid, to medical practice in 1962, 
there has been outstanding improvement in patients’ survival [72]. To date, Dex is the 
cornerstone for the management of cerebral edema with no superior alternative therapy 
[8,9]. However, Dex has been associated with numerous side effects especially with the 
long-term use of high doses, including behavioral changes, insomnia, myopathy, 
hyperglycemia, weight gain and peptic ulcer. Moreover, withdrawal of steroid therapy is 
also associated with severe side effects including steroid withdrawal syndrome (i.e. 
headache and lethargy) and adrenal insufficiency due to the lack of production of 
endogenous corticosteroids [9,10]. Therefore, there is an urgent need to discover equal or 
superior alternatives with fewer side effects. Although how Dex induces its anti-edema 
effect is largely unknown, it is thought that Dex might achieve its effect by acting on 
microglial cells [73]. Indeed, microglial secretion of key inflammatory mediators (i.e. 
matrix metalloproteinases and prostaglandin) that contributes to blood brain barrier 
(BBB) damage [74,75]. 
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The Effect of Dex on Glioma Cells 
  
Despite the intensive use of Dex for alleviating peritumoral edema, varying 
effects of Dex on glioma cells in vitro have been found in different cell systems. Grasso 
et al. demonstrated that 1 μM Dex had an anti-proliferative effect on rat glioma cultures 
[76]. Similarly, ependymoblastoma-bearing mice treated with 40 mg/kg of Dex had lower 
tumor size and showed a reduction in thymidine incorporation into DNA [35]. However, 
the effect of steroids appears to be highly dependent on their concentration. For example, 
Dex increases the proliferative capacity of human astrocytoma cultures at low 
concentration, while it is cytotoxic at high concentrations (> 50 μM) [36,77]. For the 
most part, these studies used non-physiological concentrations of Dex and/or the 
treatment schedule did not recapitulate the treatment regimen in brain tumor patients. In 
the current study Dex treatment regimen was carefully chosen to represent its use in the 
clinical settings. To be able to mimic the in vivo effect and to have reliable meaningful 
data, our in vitro cell cultures were treated with physiological concentrations of Dex. 
 
 
The Effect of Dex on Microglial Cells 
 
To add another layer of complexity there is a dynamic interaction between 
microglia and tumor cells in the tumor microenvironment. In particular, tumor cells have 
the capability to silence microglia’s immunological responses and shift their polarization 
to M2-like phenotype [78]. In return M2-like microglia secrete factors that could support 
tumor proliferation and invasion [79,80]. However, the effect of Dex on this symbiotic 
relationship has not been determined. Since GBM patients have a poor prognosis and 
very low survival rate, it becomes particularly important to identify the effect of Dex on 
both glioma cells and stromal cells. Whether Dex influences tumor microglial cell 
polarization or its consequence on the tumor progression is not precisely identified. It is 
also unknown whether Dex is interfering with the efficacy of radiotherapy and 
chemotherapy. Therefore, the aim of our study is to determine the effect of Dex on 
glioma cell proliferation as well as the effect of Dex on microglial cell number and 
phenotype.  
 
To our knowledge, this is the first study that utilizes a clinically related glioma 
mouse model to study the effects of Dex on tumor cells and tumor associated microglial 
cells. In this model, mouse gliomas recapitulate the histopathological features of human 
glioma, such as pseudopalisading necrosis, diffuse infiltration and microvascular 
proliferation [81]. Therefore, the results from this study will be pivotal since it captures 
several important features of the human disease. The Replication Competent ALV Splice 
acceptor (RCAS)/ tva system was used to induce PDGF expression in nestin-expressing 
cells. RCAS is a viral vector derived from the avian leukosis virus (ALV). Because tva 
receptor is required for viral entry, the mice have been genetically engineered to express 
the tva receptor in nestin expressing cells (Ntva). After PDGF expression in Ink4a/Arf-/- 
mice, gliomas develop in all the mice within 6 weeks post viral injection [82]. 
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Materials and Methods 
 
 
Generation of PDGF Induced Glioma Mouse Model 
 
For theses studies, we employed a PDGF-induced glioma mouse model that was 
generated in Dr. Eric Holland’s laboratory (Fred Hutchinson Cancer Research Center, 
Seattle), in which the RCAS/tva system to drive the expression of PDGF in nestin 
expressing cells (Ntva). First, the RCAS/PDGF viral vector (a generous gift from Dr. 
Holland) was used to infect and overexpress PDGF in chicken fibroblast DF-1 cells 
(DF-1/PDGF). Mock transfection (DF-1/GFP) was used to monitor infection efficiency 
with a Nikon Eclipse TE300 fluorescent microscope. Plasmid-FuGENE mixture (1:6) 
was used to transfect DF-1 cells for 48 hr. Subsequently, the cells were passaged and 
monitored with a fluorescent microscope to determine the transfection efficiency. The 
cells were maintained in DMEM media (Cellgro, Hemdon, VA) supplemented with 10% 
FBS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin. PDGF viral 
vector producing cells in the log phase (60-80%) was trypsinized and washed once with 
PBS. After counting, cells were re-suspended in PBS at 100,000 cells/μl and placed on 
ice immediately. Four to six week old Ink4a/Arf-/-/Ntva+ mice (a generous gift from Dr. 
Holland) were deeply anesthetized with a ketamine/xylene mixture. Using a stereotactic 
frame, 1 μl of cells were intracranially injected into the right frontal cortex. Starting from 
the 4th week post-injection the mice were weighed daily and monitored for any sign of 
sickness or neurological symptoms. Mice with symptoms, or those losing weight were 
placed randomly in the study (Figure 2-1). For in vivo studies, the mice were treated for 
3 days with DEX at 10 mg/kg body weight, which is expected to result in a Dex 
concentration in brain tissue of ~ 1 μM [83,84]. In order to mimic in vivo conditions, the 
primary cultures were treated with physiologically relevant doses (i.e. 0.1, 1 and 10 μM) 
of Dex.  
 
 
Primary Glioma Cultures 
 
Glioma-bearing mice were sacrificed by transcardiac perfusion using ice-cold 
PBS. The brain was removed and placed immediately in ice-cold PBS, subsequently the 
tumor was carefully dissected with surgical tweezers, and single cell suspensions 
prepared using papain dissociation system. First, the dissected tumor tissue was incubated 
with papain solution (0.94 mg/ml papain, 0.18 mg/ml EDTA, 0.18 mg/ml N-Cystein and 
0.1 mg/ml DNase in EBSS; Worthington Biochemical Corp. Lakewood, NJ) for 15 min 
at 37°C. Then, ovomucoid solution (0.7 mg/ml ovomucoid, 0.014 mg/ml DNase in 
neuro-basal media) was added to inactivate the enzymatic digestion by papain. After 
centrifugation at 1200 rpm for 10 min, the cells were washed using neuro-basal media. 
Subsequently, the cells were re-suspended in DMEM media (Cellgro, Hemdon, VA) 
supplemented with 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin. 
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Figure 2-1. A cartoon representation of the experimental design. 
 
RCAS/PDGF vector was used to infect DF-1 chicken fibroblast cells. Virus producing 
cells were then intracranially injected into Ntva+; Ink4a/Arf-/-. When mice displayed 
neurological symptoms or had lost weight they were treated with 0 or 10 mg/kg Dex for 3 
days. Tumor samples from control and treated mice were used for IHC and Q RT-PCR 
experiments. For in vitro testing, primary glioma cultures were generated from control 
tumor-bearing mice using papain dissociation system and subjected to MTT and cell 
cycle proliferation assays. 
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Immunohistochemistry  
 
Mice were anesthetized and perfused transcardially with saline followed by 10% 
formalin. Brain samples were then post-fixed in neutral buffered 10% formalin solution 
(Sigma-Aldrich, St. Louis, MO) for 24 to 72 hr. After fixation, tissue samples were 
blocked with and paraffin embedded for sectioning (4 μM thick). Following re-hydrating, 
the slides were microwaved for 10 min in citrate buffer (pH = 6.0) for antigen retrieval. 
Then the slides were incubated with 3% hydrogen peroxide solution for 3 min at room 
temperature to neutralize endogenous peroxidases. After permeabilization in 0.3% Triton 
X-100 in PBS (PBST), the sections were blocked in 2% BSA, 5% normal goat serum, 
0.1% Triton X-100 in PBS for 1 hr at room temperature. Primary antibodies were 
incubated overnight at 4°C at a dilution of 1:500 (Iba-1; Wako Chemicals Inc. Richmond, 
VA), 1:300 (Cleaved caspase-3; Cell Signaling Technology, Beverly, MA), 1:200 (Ki67; 
Vector Laboratories, Burlingame, CA) and 1:2000 (PCNA; Dako, Carpinteria, CA). After 
rinsing the slides 3 times in 0.1% PBST, the slides were incubated with biotinylated goat 
anti-rabbit secondary antibody (Vector laboratories, Burlingame, CA) for Iba-1, cleaved 
caspase-3, and Ki67. MOM kit (Vector Laboratories, Burlingame, CA) was used for 
PCNA staining. The slides were then incubated with ABC solution (Vectastain ABC 
Elite kit; Vector Laboratories, Burlingame, CA) for 30 min, washed 3 times in water and 
then incubated with DAB solution (Vector Laboratories, Burlingame, CA) until the 
brown color developed. After counterstaining the nucleus with hematoxlin 
(Richard-Allan Scientific, Kalamazoo, MI), the slides were dehydrated and mounted with 
permount mounting media (Fisher Scientific Co., Fair Lawn, NJ). Finally, the slides were 
scanned with Aperio Spectrum system and analyzed using ImageScope v11.1.2.760 
(Aperio, Vista, CA). The whole tumor regions were selected based on H&E staining and 
positive pixels and negative pixels (unstained nuclei) were counted. Percent positivity 
was calculated based on Equation 2-1; 
  
                          % Positivity = (positive pixels *100) /total pixels               (Eq. 2-1) 
 
To quantify of areas of necrosis, paraffin embedded tumor sections were stained 
with hematoxylin and eosin (H&E). Subsequently, the slides were scanned using 
Spectrum system from Aperio and analyzed using ImageScop v11.1.2.760 (Aperio Vista, 
CA). The tumor region and regions of necrosis were selected and the necrotic index was 
calculated according to Equation 2-2 [85]; 
 
Necrotic index = (Areas of necrosis (μm2)*100)/Total area of tumor section (μm2) 
   (Eq. 2-2) 
 
 
Immunofluorescence 
 
Immunofluorescence double staining was performed on re-hydrated brain 
sections. The slides microwaved for 10 min in citrate buffer pH 6.0  for antigen retrieval. 
After permeabilization in 0.3% triton X-100 in PBS (PBST), the sections were blocked in 
2% BSA, 5% normal donkey serum, 0.1% triton X-100 in PBS for 1 hr at room 
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temperature. Anti-Iba-1 (1:250; Wako Chemicals Inc. Richmond, VA) or anti-olig2 
(1:100; Millipore Co., Bedford, MA) primary antibodies were incubated overnight at 4 
°C. After rinsing the slides 3 times in 0.1% PBST, the slides were incubated with Alexa 
Fluor 555 conjugated goat anti-rabbit secondary antibody (1:500; Molecular Probes Life 
Technologies Inc., Grand Island, NY). The slides were then washed 3 times in 0.1% 
PBST and incubated with the anti-PCNA primary antibody (1:100; Dako, Carpinteria, 
CA) for 1 hr. Subsequently, the sections were incubated for 1 h at room temperature with 
Alexa Fluor 448 conjugated goat anti-mouse secondary antibody (1:500; Molecular 
Probes Life Technologies Inc., Grand Island, NY). Finally, vectashield mounting media 
(Vector Laboratories, Burlingame, CA) containing DAPI was used to stain nuclei. Slides 
were then visualized on a LSM Zeiss 700 microscope, 20X objective, 2X zoom. At least 
200 cells were analyzed per slide for Olig2+ staining and 50 cells for Iba-1+ staining. 
  
The percentage of Iba-1 positive cells were quantified in primary glioma cultures 
by immunocytochemical analysis. Cells were fixed with 4% PFA/PBS for 10 min, and 
permeabilized with 0.5% Triton X-100/PBS for 5 min. Cells were then washed with PBS 
and blocked with 3% BSA/PBS for 1 h. Cells were immunostained with anti-Iba-1 
(1:250; Wako Chemicals Inc. Richmond, VA) for 1 h. Subsequently, cells were washed 
with PBS and incubated for 1 h with in Alexa Fluor 555 conjugated goat anti-rabbit 
secondary antibody (1:500; Molecular Probes Life Technologies Inc., Grand Island, NY). 
Finally, vectashield mounting media (Vector Laboratories, Burlingame, CA) containing 
DAPI was used to stain nuclei. Slides were visualized using Nikon Eclipse TE300 
fluorescent microscope. A minimum of 100 cells were analyzed per culture for Iba-1 
staining using Adobe Photoshop CS4.  
 
 
MTT Assay 
 
Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (Sigma-Aldrich, St. Louis, MO). Primary glioma cultures were 
seeded at a density of 1000 cells/ well in 96-well plates. A 50 μl stock solution of Dex 
(Sigma-Aldrich, St. Louis, MO) was prepared by dissolving Dex in DMSO. Cells were 
allowed to attach overnight and Dex or vehicle control was added to the appropriate 
wells. After 3 days of drug exposure, MTT was added to wells and allowed to incubate 
for 3 hr. Afterwards, the media was carefully aspirated and the purple formazan crystals 
were dissolved in 100 μl DMSO (Fisher Scientific Co., Fair Lawn, NJ). Absorbance was 
measured at wavelength of 570/690 nm using a FLx800 fluorescence microplate reader 
(BioTek Instruments, Inc., Burlington, VT).  
 
 
Cell Cycle Analysis 
 
The effect of Dex on cell cycle phase distribution was measured by flow 
cytometry. Cells seeded on 10 cm plates at 4000/ml were allowed to attach to the plates 
overnight and then treated with 0.1, 1 and 10 μl Dex for 3 days. After cell trypsinization 
and washing in ice cold PBS, the cells were fixed in ice cold 70% ethanol for at least 1 
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hr. Subsequently, the cells washed with PBS and stained with 0.05 mg/ml propidium 
iodide (PI) in presence of 0.1 mg/ml RNAses and then analyzed using BD Accuri C6 
flow cytometer (BD Bioscience, San Jose, CA). A quantification of different phases of 
cell cycle (G0/G1, S, G2/M) was carried out using Modfit LT V2.0 (Verity Software 
House, Tosham, ME). 
 
 
Co-Culture Experiments 
 
To determine the role of microglia in tumor cell proliferation, co-cultures of 
microglia-tumor cells were generated. First, primary glioma cells were generated form 
control tumor-bearing mice using papain dissociation system. Since, microglial cells 
attach very well to the plate and are hard to trypsinize, we used this property to deplete 
them by mild trypsinization and serial subculturing technique. Furthermore, microglial 
cell content was determined using ICC. Glioma co-cultures containing 0%, 5 % or 10 % 
BV2 microglial cells were generated (Figure 2-2). Pure glioma cultures and microglia 
cultures were used as controls. For MTT cell viability assay, 250 cells/well in 96-well 
plates were seeded and treated with 0, 0.001, 0.01, 0.1, 1, 10, 100 μM Dex for 3 days. 
Additionally cell cycle assay was employed on single and co-cultures after 3 days of Dex 
treatment with either 0 or 10 μM. Cell proliferation assays were performed as mentioned 
above. 
 
 
Q RT-PCR 
 
Glioma conditioned media (CM) was obtained by growing 1 X105 glioma cells/ml 
of a complete media without antibiotic for 48 hs. The collected CM was filtered (0.2 μm 
filter) to remove cellular materials and stored at -20 °C. BV2 microglial cells were seeded 
at 4 X104 cells/ml in the CM and incubated overnight to allow cell attachment. The 
cultures were treated with 0 or 10 μM Dex for 3 days. Total RNA was extracted from 
BV2 cell cultures and mouse tumor samples using Trizol reagent (Invitrogen, Carlsbad, 
CA). The yield and purity of the RNA was confirmed using Nanodrop; ND-1000 V3, 
spectrophotometer. 
 
First, cDNA was synthetized using transcriptor first strand cDNA synthesis kit 
(Roche Applied Sciences, Indianapols, IN) using 1 μg of RNA.  Primer panels were 
designed using Roche Universal Probe Library to detect M1- (iNOS, IFNγ, IL-1β, TNFα, 
CD86) and M2- (Arg1, TGF-β, CD204, MMP9, IL-1ra) markers of microglia (Table 
2-1). The housekeeping gene, TBP, was used to normalize genes. Expression Q RT-PCR 
was performed using LC480 light cycler under the following conditions; 50 cycles of 
amplification, activation step for 5 min at 95°C, annealing step for 30 sec 60°C and 
finally extension step 72°C for 10 sec.  
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Figure 2-2. A cartoon illustrating tumor-microglia co-cultures. 
 
Primary glioma cultures were passaged a few times in order to deplete microglial cells. 
ICC was performed to confirm the depletion of microglial cells. Subsequently, BV2 
microglial cells were mixed with glioma cells to create glioma co-cultures containing 0%, 
5% or 10% microglial cells. 
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Table 2-1. Primer sequences used for RT-PCR. 
 
Gene 
symbol Gene name Gene ID# Probe Primer sequence 
Arg1 Arginase NM_007482.3 2 F:GAATCTGCATGGGCAAC 
R:GAATCCTGGTACATCTGGGAAC 
CD86 CD86 antigen NM_019388.3 107 F:GAAGCCGAATCAGCCTAGC 
R:CAGCGTTACTATCCCGCTCT 
CD204 Macrophage scavenger 
receptor 1 
BC003814 26 F:GGGAGTGTAGGCGGATCA 
R:GGAGATGATAGTAGGGTGCTCTG 
IL-1ra Interleukin 1 receptor 
antagonist 
BC042532 34 F:GGCAGTGGAAGACCTTGTGT 
R:CATCTTGCAGGGTCTTTTCC 
MMP9 Matrix 
metallopeptidase 9 
NM_013599.2 19 F:ACGACATAGACGGCATCCA 
R:GCTGTGGTTCAGTTGTGGTG 
iNOS Nitric oxide synthase 2 NM_010927.3 13 F:CTTTGCCACGGACGAGAC 
R:TCATTGTACTCTGAGGGCTGAC 
TGFβ Transforming growth 
factor, beta 1 
NM_011577.1 72 F:TGGAGCAACATGTGGAACTC 
R:GTCAGCAGCCGGTTACCA 
TNFα Tumor necrosis factor NM_013693.2 25 F:CTGTAGCCCACGTCGTAGC 
R:TTGAGATCCATGCCGTTG 
IL-1b Interleukin 1 beta NM_008361.3 38 F:AGTTGACGGACCCCAAAAG 
R:AGCTGGATGCTCTCATCAGG 
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Statistical Analysis 
 
Mann-Whitney U test was used to compare between two groups. Significance was 
declared when p < 0.05. All statistical analyses were performed using Statistica 8 
(StatSoft Inc., Tusla, OK). 
 
 
Results 
 
 
Generation of PDGF Driven Mouse Model of Glioma 
 
In the current study we used a mouse model of glioma that is driven by PDGF 
overexpression in neural stem cells. First, DF-1 cells were infected with RCAS PDGF or 
GFP vectors.  Fluorescent images of DF-1/GFP cells showed nearly 100% transfection 
efficiency of the cells (Figure 2-3A). Virus producing cells, DF-1/PDGF, were injected 
intracranially in Ink4a/Arf-/-/Ntva+ mice. The developed gliomas closely represent the 
pathological features of human GBM such as vascular proliferation and the formation of 
pseudopalisading necrosis structures as described previously (Figure 2-3B) [81]. 
 
 
Quantification of Cell Proliferation and Cell Death in Dex Treated Glioma-Bearing 
Mouse 
 
The precise effect of Dex on tumor cell proliferation remains unclear. Some 
studies showed that Dex decreases cell proliferation, while others showed that Dex can 
stimulate cell growth in vitro at low doses and is cytotoxic at high concentrations 
[35,36,77]. To address this question, paraffin embedded glioma sections from mice 
treated with 0 or 10 mg/kg Dex were subjected to IHC analysis. Anti-PCNA (Figure 
2-4A) and anti-Ki67 (Figure 2-4B) primary antibodies were used to specifically quantify 
proliferating cells. We found that there was a significant decrease of both markers in Dex 
treated animals (p = 0.03 and p = 0.045 respectively). Then we examined cell death 
induced by Dex treatment via quantification of caspase 3, as a marker of apoptosis, in 
tumor sections. We observed low levels caspase-3 staining in both treated and control 
tumor sections, but there was no significant difference between the two groups (p = 
0.521) (Figure 2-4C). As a second measurement of cell death, total area of necrosis has 
been quantified in tumor sections (Figure 2-4D). We found no significant difference in 
necrosis regions between the two groups (p = 0.902). To determine whether Dex 
decreases glioma cell proliferation, double immunofluorescence staining was performed 
using anti-olig2 antibody to identify tumor cells and anti-PCNA antibody as a 
proliferative marker. In agreement with DAB staining, there was a significant decrease in 
total cell proliferation in Dex treated mice (p = 0.0079) (Figure 2-5A). More 
interestingly, there was a significant decrease in proliferation in Olig2 positive cells (p = 
0.0079) (Figure 2-5B). However, it is becoming widely accepted that tumor cell growth 
is greatly influenced by microglial cells [79,86]. Therefore, we investigated the effects of 
Dex on microglial cell content in tumor sections. 
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Figure 2-3. PDGF-induced mouse model of glioma. 
 
A, DF-1 chicken fibroblast cells were infected with RCAS/PDGF or RCAS/GFP vector. 
DF-1/GFP cells were used to confirm transfection efficiency using Nikon eclipse TE300 
fluorescent microscope 20X objective. B, H&E staining of tumor sections showing 
vascular proliferation (left panel) and areas of necrosis area in the right panel (white 
arrows). 
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Figure 2-4. IHC analysis of cell proliferation. 
 
A, PCNA staining was significantly reduced in Dex treated tumor sections compared to 
the control sections (P = 0.03948). B, Ki67 staining showed that Dex treated mice had 
significantly less proliferating cells compared to the controls (P = 0.045). C, Cell death 
was quantified using anti-cleaved caspase-3 primary antibody. The percentage of 
caspase-3 positive cells was very low in both treated and control tumor sections and there 
was not a significant difference between groups (P = 0.521). D, Total areas of necrosis 
were not significantly different between Dex treated and control mice (P = 0.9015). Bars 
represent the means; whiskers represent the standard deviation (±); * p < 0.05. 
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Figure 2-5. IHC analysis of glioma cell proliferation. 
 
Tumor sections were double stained with anti-Olig2  (marker of glioma cells) and PCNA 
(proliferative marker) primary antibodies. A, Total PCNA+ cells were significantly lower 
in Dex treated samples compared to the controls (P = 0.0079). B, There was a significant 
decrease in the proliferation of Olig2+ cells after Dex treatment (P = 0.0079). Nuclei 
stained in blue (DAPI), PCNA stained in green (Alexa fluor 488) and Olig2 stained in red 
(Alexa fluor 555); (Zeiss LSM 700 Laser Scanning Microscope, 400x magnification). 
Bars represent the means; whiskers represent the standard deviation (±); * p < 0.05. 
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IHC Analysis of Microglial Cell Number and Proliferation Following Dex 
Treatment 
 
To determine the effect of Dex on microglial cell content in the tumor 
microenvironment, IHC analysis was employed to quantify microglial cells in tumor 
sections. Using anti-Iba-1 primary antibody to specifically stain microglia/macrophages., 
there was a significant reduction in Iba-1+ cells in Dex treated tumor sections when 
compared to the untreaded mice (p = 0.0299) (Figure 2-6A). Next we investigated 
whether the decrease in microglial cell content is accompanied with a decrease in 
microglial cell proliferation. To test this possibility, tumor sections from both control and 
Dex treated mice were double stained with anti-Iba-1 and anti-PCNA primary antibodies. 
Indeed, there was a significant decrease in microglial proliferation in the Dex treated 
group when compared to the control group (p = 0.0138) (Figure 2-6B). 
 
 
Gene Expression Analysis of Markers Associated with M2- and M1-Like Microglia 
Phenotypes 
 
In the tumor microenvironment, microglial cells are being reprogrammed by 
glioma cells to create an immunosuppressive environment as well as to promote tumor 
cell growth and invasion [78]. This type of activated microglia is known as M2-like 
microglia. In contrast M1-microglia are characterized by immune reactivity and induction 
of inflammation responses [78]. Therefore, we first analyzed microglial cell polarization 
to both phenotypes in our glioma mouse model. Total RNA was extracted from tumor 
samples obtained from control tumor-bearing mice using trizol method. We employed Q 
RT-PCR to assess the expression of various genes that are related to M2- (Arg1, TGF-β, 
CD204, MMP9, IL-1ra) and M1- (iNOS, IL-1β, TNFα, CD86) phenotypes. There was an 
obvious overexpression of TGF-β, MMP9 and Arg1 were expressed at high levels when 
compared to any of M1-markers that have been tested (Figure 2-7). CD204 is a cell 
surface marker of M2-cells and showed a similar level of expression to iNOS and higher 
expression compared to other M1-markers; IL-1β, TNFα, CD86. In agreement with 
previous findings, tumor associated microglial cells exhibit on M2-like phenotype, which 
could promote tumor cell proliferation and progression [79,86]. However, we observed a 
decrease in tumor cell proliferation in Dex treated group, therefore we investigated 
whether Dex exhibits its anti-proliferation properties by modulating M2-like phenotype 
of microglial cells.  
 
 
The Effect of Dex on Microglial Cell Polarization 
 
We assessed gene expression of M1- and M2-signature genes in BV2 microglial 
cultures. The cells were grown in glioma CM and treated with 0 or 10 μM Dex for 3 
days. Total RNA was extracted using Trizol method, and Q RT-PCR was employed using 
1μg of cDNA. Dex treatment resulted in a significant decrease (p ≤ 0.005) in relative 
gene expression of M2-associated genes (i.e. CD204, TGFβ, MMP9 and IL-1ra) when 
compared to the controls (Figure 2-8A). Next, we examined gene expression in vivo  
 26 
 
 
 
Figure 2-6. IHC analysis of microglial cell number and proliferation following 
Dex treatment. 
 
A, Total number of microglial cell was quantified in paraffin embedded tumor sections 
stained with anti-Iba-1 primary antibody. Dex significantly reduced microglia content in 
vivo (p = 0.0299). B, Tumor sections were double stained with anti-Iba-1 antibody as a 
marker of microglial cells and PCNA as a proliferative marker. There was a significant 
reduction in the proliferation of microglial cells after Dex treatment (P = 0.0138). Nuclei 
stained in blue (DAPI), PCNA stained in green (Alexa fluor 488) and Iba-1 stained in red 
(Alexa fluor 555); nuclei stained in red (Zeiss LSM 710 Laser Scanning Microscopes, 
400x magnification). Bars represent the means; whiskers represent the standard deviation 
(±); * p < 0.05. 
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Figure 2-7. Q RT-PCR analysis of the genes associated with M1- and 
M2-microglial phenotypes.   
 
Total RNA was extracted from tumor-bearing mice and Q RT-PCR was performed using 
Taqman probes. M2-markers of microglia (TGFβ, MMP9, Arg1, and CD204) were 
overexpressed compared to M1-markers (iNOS, TNFα, IL-1β and CD86). Bars represent 
the means; whiskers represent the standard deviation (±). 
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Figure 2-8. Q RT-PCR analysis of genes associated with microglial polarization in 
control and Dex treated tumor samples. 
 
Total RNA was extracted from BV2 microglia cultures that were grown in glioma 
conditioned media and treated with 0 or 10μM Dex for 3 days. In addition, RNA was 
extracted from tissue samples of tumor-bearing mice treated with 0 or 10 mg/ml Dex. Q 
RT-PCR was employed to analyze a panel of genes associated with M2- and 
M1-phenotypes of microglia. A, Relative gene expression analysis showed that Dex 
treatment significantly decreased M2-associated genes (i.e. CD204, TGFβ, MMP9, and 
IL-1ra) in BV2 microglial cultures. B, The same trend was observed in glioma samples. 
There was a decrease in MMP9, IL-1ra and Arg1 relative expression compared to TBP. 
C, Dex treatment was associated with a significant decrease of all M1-associated genes 
(i.e. CD86, iNOS, TNFα, IL-1β) in vitro. D, However, in Dex treated animals, while 
there was no change in the relative expression of CD86 and iNOS, there was a significant 
increase in TNFα and IL-1β expression. Bars represent the means; whiskers represent the 
standard deviation (±); * p < 0.05. 
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using glioma samples from control and Dex-treated mice. Consistent with the in vitro 
results, Dex treatment was associated with an inhibition of M2-like microglial cells. 
There was a modest decrease in relative gene expression of MMP9 and IL-1ra (Figure 
2-8B). In BV2 cultures, the relative expression of M1-signature genes including CD86, 
iNOS, TNFα and IL-1β significantly was decreased in Dex treated samples (p ≤ 0.005) 
(Figure 2-8C). In contrast to in vitro results, there was a significant increase in the 
expression of inflammatory cytokines; TNFα and IL-1β (p ≤ 0.01) (Figure 2-8D). The 
expression of CD204 or CD86 surface markers of M2- and M1-like microglial cells, 
respectively, was not altered in Dex treated tumor-bearing mice. Finally, we observed a 
slight increase in expression of TGFβ and iNOS in Dex treated mice compared to the 
control mice. Whether the decrease in M2-like microglial cells in tumor 
microenvironment could play a role in the decrease of tumor cell proliferation remains to 
be elucidated. 
 
 
In Vitro Proliferation Assessment of Primary Mixed Glioma Cultures 
 
Theoretically, Dex’s inhibitory effect on M2, pro-tumor, microglial cells could 
play a role in the inhibition of tumor cell proliferation. To investigate this hypothesis, we 
established primary glioma cultures from control tumor-bearing mice. Glioma cultures at 
low passages (1-3) were used as in vitro model of mixed cultures of both tumor and 
stromal microglial cells. To test the ability of maintaining microglial cells in vitro, we 
performed ICC staining for microglia in these cultures. MTT cell viability assay was 
employed on glioma cultures treated with escalating doses of Dex (0.001- 100 μM). For 
all glioma cultures tested, there was no inhibitory effect of Dex (Figure 2-9A). 
Additionally, ICC staining showed the presence of microglial cells (6%) (Figure 2-9B). 
Furthermore, cell cycle analysis was performed on glioma cultures at low passages 
treated with physiologically relevant Dex doses (i.e. 0, 0.1, 1 and 10 μM) for 3 days by 
flow cytometry based technique. Although there was an a slight increase in the 
percentage of G1 phase after Dex treatment, which might imply a cell cycle arrest, this 
subtle increase may not be biologically important (Figure 2-9C). In addition ICC 
staining demonstrated the presence of 10% Iba-1+ cells in this culture (Figure 2-9D). 
Therefore, in vitro cell proliferation assays did not indicate a change in the proliferation 
of mixed primary glioma cultures. To further validate our findings, we generated 
microglia-glioma co-cultures and compared it to pure glioma cultures to address the 
question of whether Dex influences tumor cell proliferation indirectly by affecting 
microglial cells. 
 
 
The Effect of Dex on Glioma-Microglia Co-Cultures 
 
To determine the role of microglia in the cross talk between microglia and tumor 
cells, co-cultures of microglia-tumor cells was generated (Figure 2-2). Primary mouse 
glioma cultures were sub-cultured several times in order to deplete microglial cells. ICC 
staining using anti-Iba-1 primary antibody was used to confirm the depletion of 
microglial cells (Figure 2-10A). Subsequently, BV2 microglial cells were added to the  
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Figure 2-9. In vitro cell proliferation assays using primary mixed glioma cultures. 
 
A, MTT assay for cell proliferation in vitro. Dex did not show an effect on cell 
proliferation in vitro after 3 days of incubation. B, ICC staining for Iba-1+ cells showed 
6% of a microglial cells in primary mouse glioma cultures. C, Cell cycle analysis was 
performed on glioma cultures treated with 0.1, 1 and 10μM of Dex for 3 days. Although 
there was an increase in G1 phase and a subsequent decrease in G2 phase, the observed 
difference was not considered to be biologically significant. D, ICC staining for Iba-1+ 
cells showed 10% of a microglial cells in primary mouse glioma cultures. Bars represent 
the means; whiskers represent the standard deviation (±). 
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Figure 2-10. The effect of Dex on glioma-microglia co-cultures. 
 
A, ICC staining for Iba-1+ cells showed a microglial cells depletion in primary mouse 
glioma cultures. B, Glioma and microglial single cultures and co-cultures were plated in 
96-well plates and treated with escalated doses of Dex for 3 days. There was not decrease 
in cell viability under any of the conditions tested. C, Glioma and microglial single 
cultures, and co-cultures were subjected to cell cycle analysis assay to assess the effect of 
Dex on cell proliferation. We have not observed any Dex induced cell death (Sub-G1) or 
cell cycle arrest at either G1 or G2 phase of the cell cycle. Bars represent the means; 
whiskers represent the standard deviation (±). 
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Figure 2-10. Continued. 
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glioma cultures at 0%, 5% or 10% and seeded in 96-well plates for MTT assay or T75 for 
cell cycle assay. Single cultures of glioma and BV2 cells were used as controls. After 
overnight incubation to allow cell attachment, the cultures were treated with Dex for 3 
days. The percentage of cell viability of all the cultures did not decrease when treated 
with 0.001-10 μM Dex. Only at 100 μM, Dex was able to reduce cell viability of 
microglia and co-cultures. However, 100 μM is not a physiologically relevant dose of 
Dex (Figure 2-10B). Quantification of various phases of cell cycle did not reveal a 
dramatic change in glioma cell proliferation either in single cultures or co-cultures with 
microglial cells. However, we observed a subtle increase, in the G2/M phase after Dex 
treatment in glioma cells co-cultured with 10% microglial cell (Figure 2-10C). This 
might indicate a modest cell cycle arrest at G2 phase of the cell cycle. However, Dex 
significantly increased microglial cell proliferation when not co-cultured as well as 5% 
co-culture as shown by decreasing G0/G1 phase and increasing S phase. This effect has 
not been observed in MTT assay or in vivo results, which emphasize the importance of 
the native microenvironment to the tumor cell responsiveness. 
 
 
Discussion 
 
GBM is one of the most devastating types of cancer, because it has a very poor 
prognosis. For the past 10 years, the overall survival has not improved, with estimated 
survival of 3 years for only 7% of the patients [2]. Furthermore, all aggressive gliomas 
develop vasogenic edema. These corticosteroids have been used to, quickly, improve 
neurological symptoms resulting from edema formation [9,72]. However, the use of 
corticosteroids has been associated with numerous side effects including behavioral 
changes, peptic ulcer, hyperglycemia, weight gain and others [9,10]. Despite the intensive 
use of Dex in the clinic, its exact effect on the biology of glioma disease is not precisely 
identified. This is particularly important in regard to the effect of Dex on the 
responsiveness of glioma to chemo- and radiotherapy. Therefore, the aim of the current 
study is to investigate the effects of Dex on glioma and microglial cells in a 
PDGF-induced glioma mouse.  
 
 
The Anti-Proliferation Properties of Dex 
 
Whether Dex has anti-proliferative or anti-neoplastic properties, or it stimulates 
cell growth has been a long debate in the literature [35,36,76,77]. To understand the 
effect of Dex on cell proliferation, we employed a mouse model that resembles the 
human disease. To our knowledge this is the first study that utilizes a relevant mouse 
model of glioma to study the action of Dex in this mouse model. Overexpressing PDGF 
oncogene in neural stem cells using ink4a/Arf -/- mice drives the gliomagenesis in 100% 
of mice, 6 week post-infection [82]. The uniqueness of this model is that it is closely 
mimicking the molecular and pathological features of human GBM [81]. In addition, we 
employed physiological doses of Dex in our studies. Therefore, in the current study mice 
will be treated with a clinically relevant concentration of Dex (10 mg/kg) every day for 3 
days. The human equivalent dose of 10 mg/kg is 0.8 mg/kg [83]. Indeed, at the time of  
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clinical presentation, patients received 16-100 mg/day of Dex (0.27-1.67 mg/kg) 
[9,83,87,88].  
 
In our genetically engineered mouse model, we found that Dex treatment 
decreases tumor cell proliferation as shown by PCNA and Ki67 IHC staining (Figure 2-4 
and Figure 2-5). However, we did not observe significant levels of cell death in Dex 
treated samples. This indicates that Dex exhibits anti-proliferative activity in our mouse 
model. This finding can be interpreted in different ways. On one hand, several studies 
showed a strong correlation between PCNA proliferation index and patient’s survival. In 
particular, better prognosis and improved patient survival are correlated with low 
proliferative index [89-91]. However, cancer therapeutics often target rapidly dividing 
cells, it becomes quite possible that Dex might compromise the responsiveness of tumor 
cells to chemotherapy and/or radio-therapy by slowing down tumor cell replication. 
Indeed, the use of corticosteroids was shown to increase tumor’s radioresistance and 
chemoresistance [37,92,93]. GBM and fibroblast cell lines did not acquire resistance to 
ionizing radiation, whereas some of the carcinoma cell lines did [37,94]. Upregulation of 
steroids receptors following ionizing radiation therapy may be a potential mechanism 
responsible for Dex-induced radioresistance [38]. Such findings highlight the desperate 
need to understand the exact effect of Dex on tumor cells especially for patients 
undergoing chemotherapy or radiotherapy concurrently with corticosteroids. 
 
The mechanism of how Dex alleviates cerebral edema is mostly unknown. 
However, it has been proposed that Dex might improve peritumoral edema through its 
anti-inflammatory effect or by inhibiting microglia cells [68,73]. Microglial cells are the 
dominant immune cells in the brain, comprising 5-20% of total glial cells and up to 
approximately 35% in the glioma [95,96]. In the current study, we found that Dex 
decreases microglial cell content in tumor sections as confirmed by anti-Iba-1 primary 
antibody (Figure 2-6A). Perhaps this decrease in microglial cell content is due to slowing 
the proliferation rate (Figure 2-6B). However, two different phenotypes of microglial 
cells exists; M1 and M2. M1-like microglial cells are known to possess pro-inflammatory 
properties. On the other hand, various studies suggested that tumor-associated microglia 
could support the tumor proliferation and growth, and possess an M2-like 
anti-inflammatory phenotype [78,97,98].  
 
 
Tumor Associated Microglial Cells Possess M2-Like Phenotype 
 
In agreement with previous findings, we found that tumor associated microglia 
exhibit an M2-phenotype in PDGF-induced gliomas (Figure 2-7). Assessment of 
M1- and M2-signature gene expression reveals a shift in the microglia phenotype towards 
less M2-like (MMP9 and IL-1ra) in both in vitro and in vivo samples upon Dex treatment 
(Figure 2-8A). On the other hand, the expression of M1-associated genes was 
inconsistent when in vitro data was compared to in vivo gene expression (Figure 2-8B) 
raising the concern of the reliability of the in vitro models. We observed a decrease in the 
expression of IL-1ra and Arg1, anti-inflammatory genes, in Dex treated tumor samples. 
Of notice, IL-1ra is an antagonist to IL-1β and Arinase1 competes with and iNOS 
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substrate [99,100]. When this finding is combined with the observed modest increase in 
TNFα and IL-1β pro-inflammatory cytokines, it becomes quite obvious that Dex might 
not relieve the edema through its anti-inflammatory effect. However, our study was 
conducted after 3 days of Dex treatment, it would be very interesting to investigate the 
effect of Dex on microglial cell polarization over a prolonged period of time. 
 
 
Dex Decreases Microglial Cell Polarization to M2-Phenotype 
 
Interestingly, Dex treatment was associated with a decrease in MMP9 expression, 
possibly leading to suppression of glioma invasion. MMP9 is a member of matrix 
metalloproteinases family, which is produced primarily by immune cells such as 
macrophages/microglias and neutrophils [101]. MMP9 plays a pivotal role in tumor 
progression and invasion [97]. MMP9 deficient mice had less lung metastases in both 
melanoma and lung carcinoma animal models [102]. More importantly, MMP9 plays an 
important role in angiogenesis and induction of cell proliferation [101,103,104]. These 
findings raise the question of whether this decrease in M2-pro-tumor phenotype could 
play a role in tumor cell proliferation in Dex treated samples. Therefore, we investigated 
the anti-proliferative effect of Dex using low passage glioma cultures containing both 
tumor and microglial cells. Quite unexpectedly, we could not detect a cell proliferation 
inhibition following Dex treatment (Figure 2-9). We tested several cultures that contain 
variable percentages of microglial cell. However an anti-proliferative effect of Dex was 
not detected. To further elucidate the potential role of microglia in tumor cell 
proliferation, we established glioma-microglial cells cultures and examined glioma cell 
proliferation in Dex treated culture with and without microglial cells. However, we could 
not detect a decrease in the proliferative capacity of either glioma nor microglial cells as 
single or co-cultures. On the other hand, our in vivo data confirm a decrease in 
proliferation of both cell types following Dex treatment. These contradicting findings 
highlight the difference between in vitro and in vivo conditions and this does not 
eliminate the possibility that microglial cell play an important role in supporting tumor 
cell proliferation.  
 
In conclusion, Dex treatment is associated with a decrease in tumor and 
microglial cell proliferation in PDGF-driven glioma samples. Furthermore, pro-tumor 
microglial phenotype, M2 seems to decrease after Dex treatment. Taken together, Dex 
might act against glioma favorable conditions in our mouse model. However, this effect 
might or might not be recapitulated when Dex is combined with DNA damaging agents 
such as ionizing radiation. The current study shows the importance of studying the exact 
mechanism of action of Dex in the context of glioma. 
 
  
 38 
CHAPTER 3.    THIOPURINE-INDUCED TOXICITY IN ASTROCYTES IS 
DEPENDENT ON TPMT ACTIVITY* 
 
 
Introduction 
 
 
TPMT History and Discovery 
 
Thiopurine methyltransferase (TPMT) has been studied extensively because of its 
critical role in the methylation of thiopurine agents and their subsequent metabolites. 
Primarily, this biotransformation leads to the inactivation of these agents. Thiopurine 
drugs, such as thioguanine (TG), mercaptopurine (MP) and azathiopurine (AZA) are 
widely used as anticancer and anti-inflammatory agents and as immunosuppressants. 
However, since the use of these agents has been linked with the development of 
secondary brain tumors in TPMT-deficient patients, it is pivotal to understand the toxicity 
effects of thiopurines in the brain [42,47]. 
 
The activity of partially purified human TPMT was studied for the first time in 
1978 [105] and the first application of activity measurements was done in 1980 [106]. 
These studies raised the possibility that human RBC TPMT activity is inherited and 
TPMT genetic polymorphism is contributing to inter-individual differences in the 
metabolism of thiopurines. It was not until 1995 that the first inactive TPMT allele had 
been identified [107]. TPMT is found in the cytoplasm of eukaryotes and prokaryotes 
[108]. It catalyzes S-methylation of aromatic and heterocyclic compounds (including 
thiopurines) using S-adenosyl-L-methionine [41] however, the endogenous substrate for 
TPMT is yet to be identified. Human TPMT gene has 10 exon and is located in 
chromosome 6p22.3 [109,110]. The gene encodes a 28 kDA protein and is comprised of 
245 amino acids [111].  
 
 
Metabolism of Thiopurine Drugs 
 
Thiopurines are pro-drugs that must be metabolized intracellularly by 
hypoxanthine phosphoribosyl transferase  (HPRT) to TG nucleotides (TGN) to exert their 
cytotoxic effect [39]. First, AZA can be converted non-enzymatically to MP, which is 
then converted to thioinosine monophospahte (TIMP) by HPRT (Figure 3-1). The same 
enzyme catalyzes the conversion on TG to thioguanosine monophospahte (TGMP). 
Thioxanthiosine monophosphate (TXMP) and inositol monophosphate dehydrogenase 
(IMPDH) catalyze the conversion of TIMP to TGMP, which is subsequently converted to 
TGN. TGN is a good substrate for DNA polymerases and hence is incorporated into 
 
 
------------------------------------ 
*Adapted with permission from Hosni-Ahmed A, Barnes JD, Wan J, Jones TS (2011) Thiopurine 
methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after 
thioguanine exposure. PLoS ONE 6: e29163. 
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Figure 3-1. Thiopurine drug metabolism pathway. 
 
Azathioprine (AZA) is a prodrug of mercaptopurine (MP). Thioguanine (TG) and MP 
can be converted by hypoxanthine phosphoribosyl transferase (HPRT) to thioguanine 
nucleotide (TGNs) metabolites. MP can also be converted to the methylthioinosine 
monophosphate (meTIMP) by thiopurine methyltransferase (TPMT), which is purine 
synthesis inhibitor; however, thioguanine bypasses the conversion to this metabolite. 
Thiopurines can be converted to inactive metabolites [i.e. methyl-mercaptopurine 
(meMP); methyl-thioguanine (meTG); and methyl-thioguanine nucleotides (meTGNs)] 
by TPMT. TGN metabolites can be incorporated into DNA and RNA leading to cell 
death. However, DNA incorporation is believed to be the primary mode of cytotoxicity. 
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DNA. At steady state levels, approximately 105 to 106 TGN incorporates into DNA per 
cell [112,113]. However this level of DNA incorporation is tolerated by the cell and 
further modification, via non enzymatic methylation, of TGN (me-TGN) is required for 
its toxic effects. Me-TGN could induce single strand breaks in the DNA, interstrand cross 
links and sister chromatid exchange [114-117]. On the other hand, thiopurine agents and 
their metabolites can be inactivated by xanthine oxidase and, more importantly, TPMT 
into thiopuric acid and 6-methyl derivatives respectively. Therefore, TPMT activity is 
inversely correlated with TGN and toxicity levels [118].  
 
 
TPMT Genotypes 
 
The heterogeneity in TPMT activity is predominantly due to single nucleotide 
polymorphisms (SNPs). Despite the fact that 29 TPMT variant alleles have been 
identified [119], TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C variants account for 
approximately 90% of cases with reduced enzymatic activity [43,120-124]. TPMT*2, the 
first variant allele discovered, consists of G238C SNP which results in Ala80Pro amino 
acid substitution [107]. This substitution leads to the distortion of the tertiary structure of 
the TPMT protein and the loss of catalytic activity. However, the most clinically relevant 
mutant allele is TPMT*3A which is characterized by two SNPs; G460A at exon 7 and 
A719G at exon 10. These two SNPs result in Ala154Thr and Tyr240Cys amino acids 
substitutions. Heterologous expression of human TPMT*2, TPMT*3A in yeast showed 
enhanced proteolysis with a 15 min half live of the two mutant variants as compared with 
18 hr for the wild-type TPMT [43]. When expressed in mammalian cells, TPMT*3B and 
TPMT*3C variants, showed an enhanced degradation rate [125]. They consist of 
individual Ala154Thr and Tyr240Cys SNPs, respectively. 
 
The frequency of mutant TPMT variants differs among various ethnic 
populations. For example, TPMT*3A is the most prevalent variant allele in American 
Caucasian, Germans, Italians and Jordanians [126-129]. In addition, TPMT*3A is the 
only detected variant allele in West Asia population [130]. However, TPMT*3A is 
predominant in African-Americans, Egyptians and Ghanaians [126,131,132].  
 
Although TPMT genotypes are a good predictor of TPMT activity, non-genetic 
factors might also influence the enzyme activity. For example, thiopurines have been 
shown to induce TPMT activity [133]. On the other hand aspirin and sulfasalazine are 
potent inhibitors of TPMT when co-administered with thiopurines [134].  
 
 
TPMT Phenotypes 
 
TPMT activity is the best predictor of thiopurine efficacy and toxicity. TPMT 
deficient patients are at high risk of life threatening hematopoietic toxicity when treated 
with a standard dose of thiopurine drugs, due to accumulation of TGNs at high levels  
[44-46,135-137]. Weinshilboum and Sladek [106] reported a trimodal distribution in 
TPMT activity. The level of TPMT protein expression is directly correlated TPMT 
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protein activity. Approximately 90% of the population are homozygous for wild-type 
(WT) TPMT alleles and have high TPMT activity, about 10% are hetrozygous with 
intermediate protein activity and ~0.3% are homozygous for variant alleles, and lack 
detectable enzyme activity. Enhanced TPMT protein degradation, as compared to the WT 
TPMT, has been shown to be the mechanism that is responsible for low TPMT activity 
caused by variant alleles [43].  
 
 
TPMT Importance in the Clinical Settings 
 
Thiopurines are antimetabolites that have been used as anti-cancer agents and as 
immunosuppressants. Since the 1950s, thioguanine and mercaptopurine have been used 
to treat childhood acute lymphoblastic leukemia (ALL) [55,56]. Several studies have 
indicated inter-patient variability in TGN concentrations [137-140]. TPMT 
polymorphisms and differences in 6-MP absorption could in part explain inter-patient 
variability [46,118,141,142]. With regard to treatment outcome in children with ALL, 
high TGN concentrations have been associated with a better relapse-free survival 
compared to patients with lower TGN concentrations [137,143]. TPMT phenotype is a 
good predictor for thiopurine efficacy and toxicity. For example, a better outcome is 
associated with lower TPMT activity [41]. In general, mutant homozygous or 
heterozygous patients with low TPMT activity should be treated with lower thiopurine 
doses to avoid toxicity. Several studies have shown that TPMT deficient patients treated 
with 6-MP and receiving cranial irradiation have a high incidence of secondary brain 
tumors [47].  
 
Azathioprine and 6-mercaptopurine are widely used to treat inflammatory bowel 
disease. It has been shown that TPMT SNPs are associated with thiopurine-induced 
adverse drug reactions and bone marrow toxicity but not hepatotoxicity or pancreatitis 
[144]. In the same line of evidence, TPMT polymorphisms have been associated with 
azathioprine toxicity in renal transplant recipient patients [145]. TPMT is constitutively 
expressed in several tissues including blood, kidney, liver, and brain [146-150]. The 
association of TPMT status with brain tumor risk after thiopurine exposure prompts the 
question of whether TPMT genotypes can predict thiopurine drug phenotypes in 
astroglial cells. The relevance of TPMT status to thiopurine-associated phenotypes in 
important brain cell populations has not been studied. Indeed, the first step to address the 
question of whether TPMT plays any role in brain cancer risk after thiopurine treatment 
is to determine whether TPMT phenotypes in the brain are similar to those from other 
tissues. Thiopurine drug-associated genotoxicity has been linked to mutagenesis and 
transformative events [151-153]. We hypothesize that TPMT deficiency can lead to 
greater genotoxicity (i.e. DNA damage) and cytotoxicity in astroglial cells after 
thiopurine exposure. To address this hypothesis we used primary astrocytes isolated from 
transgenic mice of each TPMT genotype and performed in vitro studies to compare 
thiopurine-induced cytotoxicity and DNA damage between TPMT genotypes. We also 
used established human glioma cell lines as model astroglial cells to validate the findings 
observed in primary mouse astrocytes. 
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Methods and Materials  
 
 
Animals  
 
The TPMT knockout mice were a generous gift of Dr. Mary Relling (St. Jude 
Children's Research Hospital). The TPMT +/-, and TPMT -/- mice were indistinguishable 
from TPMT +/+ mice by appearance, life span, and organ histology (i.e. brain, liver, 
spleen, intestine, thymus, and lymph nodes). Animals were maintained in accordance to 
NIH guidelines for the care and use of laboratory animals and were housed in an 
AAALAC accredited facility. The University of Tennessee Health Science Center 
Institutional Animal Care and Use Committee approved all animal procedures. 
 
 
Primary Astrocyte Cultures and Cell Lines 
 
Astrocyte cultures were established from 2-5 day old pups of each TPMT 
genotype. The DNA extracted from tail snips was used to confirm TPMT genotype. A 
dissecting microscope was used to remove the meninges and hippocampus, and the 
cortices were mechanically dissociated. Subsequently, cultures were established and 
maintained in Dulbecco’s modified Eagle’s medium/Ham's F-12 50/50 mix (Cellgro, 
Hemdon, VA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 
IU/ml penicillin, 100 μg/ml streptomycin and 20 ng/ml epidermal growth factor 
(Millipore Co., Bedford, MA) and grown in Primaria flasks, (BD Bioscience, San Jose, 
CA). Cells were refed with 20 ng/ml epidermal growth factor after three days of 
incubation, and the media was changed after five days. At passage 2 three individual 
primary cultures of the same genotype were pooled and seeded for experiments. Only 
cultures with greater than 80% astrocyte purity as determined by GFAP 
immunohistochemistry were included in experiments.   
 
The T98 and A172 human glioma cell lines were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). T98 cells were grown in 
Minimum Essential Medium Eagle (Cellgro, Hemdon, VA), supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium 
pyruvate, 100 IU/ml penicillin, and 100 μg/ml streptomycin. A172 cells were grown in 
Dulbecco’s Modified Eagle’s Medium (Cellgro, Hemdon, VA), supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin. All cell cultures were maintained at 37°C in a 5% CO2 humidified 
atmosphere. 
 
 
Lentiviral Transduction 
 
 Human TPMT cDNA was obtained by digesting pCMV6-TPMT plasmid 
(OriGene Technologies, Inc., Rockville, MD) at the BamHI and EcoRI sites. TPMT 
cDNA was then amplified by PCR, purified through agarose gel electrophoresis, and 
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subcloned into BamHI and EcoRI sites of pLenti-pgk-puro vector (Viral vector core, 
UTHSC) (Figure 3-2). The pLenti-TPMT-pgk-puro and pLenti-GFP-pgk-puro lentivial 
vectors were produced in 293T cells [154]. The lentiviral vectors were used to transfect 
the A172 cell line in the presence of 6 μg/mL polybrene (Sigma-Aldrich, St. Louis, MO). 
Transfection efficiency was monitored by GFP expression using fluorescent microscope. 
The mock- (A172mock) and TPMT-transfected (A172TPMT) cell lines were seeded for 
experiments at comparable passage numbers and TPMT activity was measured prior to 
the experiments. 
 
 
Cell Proliferation Comparison 
 
The doubling rates for primary astrocyte cultures were determined and used as an 
index of cell proliferation. At passage two, 75,000 cells/well were seeded in duplicate 
6-well plates. The cells from one well of each plate were harvested daily using 0.05% 
Trypsin-EDTA (Gibco, Life Technologies Inc., Grand Island, NY) and viable cells were 
counted by trypan blue. Doubling rates were calculated based on Equation 3-1. T2 = 
Harvesting time, T1 = Initial time, N = Final cell concentration, and N0= Initial cell 
concentration. The mean doubling rate was calculated from duplicate experiments. 
 
         Doubling time (hr) = (T2-T1)/ [log2 x (Log N-Log N0)]         (Eq. 3-1) 
 
 
TPMT Activity Assay 
 
Primary mouse astrocyte and human glioma cell lines were sonicated to perform 
the TPMT activity assay. The level of TPMT activity was determined using a 
non-chelated radiochemical assay [105,147] with minor modifications. TPMT activity 
was quantitated by measuring the conversion of 6-mercaptopurine (Sigma-Aldrich, St. 
Louis, MO) to radioactively labeled 6-methylmercaptopurine with [14C] 
S-adenosyl-L-methionine (SAM) (Perkin Elmer, Waltham, MA). The protein 
concentration of each lysate was measured prior to performing the assay and was used to 
calculate TPMT activity. The mean activities for each genotype were calculated using 
data from triplicate assays.  
 
 
MTT Assay 
 
Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, MO). In brief, 1000 cells were 
seeded per well in 96-well plates. Plates were pre-coated with poly-L-ornithine 
(Sigma-Aldrich, St. Louis, MO) and laminin (Invitrogen, Carlsbad, CA) for primary 
astrocytes to facilitate cell attachment. A stock solution (15 mM) of TG (Sigma-Aldrich, 
St. Louis, MO) was prepared by dissolving TG in 0.1 N NaOH. Cells were allowed to 
attach overnight and TG or vehicle control was added to the appropriate wells. After five 
days, MTT was added and allowed to incubate for 3 hr. The media was carefully 
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Figure 3-2. pLenti-pgk viral vector. 
 
TPMT or GFP cDNA was subcloned into pLenti-pgk-puro vector using BamHI and 
EcoRI sites. The lentivial vectors were packaged in 293T cells. The mock- (A172mock) 
and TPMT-transduced (A172TPMT) cell lines were generated by transducing A172 cell 
line with either pLenti-TPMT-pgk-puro or pLenti-GFP-pgk-puro lentivial 
vector, respectively. 
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aspirated and the purple formazan crystals were dissolved in 100 μl DMSO (Fisher 
Scientific Co., Fair Lawn, NJ). Absorbance was measured using a FLx800 fluorescence 
microplate reader (BioTek Instruments, Inc., Burlington, VT). 
 
 
Alkaline Comet Assay  
 
The comet assay was performed according to the protocol established by the 
laboratory of Dr. Peter McKinnon (St. Jude Children's Research Hospital) [155]. In brief, 
50,000 primary astrocyte or 30,000 human astroglial cells were seeded in Primaria 
24-well plates (BD Bioscience, San Jose, CA) or in Falcon 24-well plates (BD 
Bioscience, San Jose, CA), respectively. Cells were allowed to attach overnight and then 
exposed to TG for three days. Thereafter, the cells were harvested and counted to prepare 
a 3 x 105 cells/ ml suspension in PBS. The cell suspension was mixed with 1.2% 
ultra-pure low melting point agarose (Invitrogen, Carlsbad, CA) and then casted onto 
chilled fully frosted glass slides (Fisher Scientific Co., Fair Lawn, NJ) pre-coated with 
0.6% agarose (Bio-Rad, Richmond, CA). The cells were lysed for 1.5 hr at 4°C in lysis 
buffer (100 μM EDTA, 2.5 M NaCl, 10 mM Tris, 1.3% Triton X-100 and 3.3% DMSO). 
The slides were washed twice with distilled H2O and incubated for 45 min at 4°C in 
electrophoresis buffer (1 mM EDTA, 50 mM NaOH and 1% DMSO). Electrophoresis 
was conducted at 12 V and ~90 mA at 4°C for 25 min. Slides were incubated for one hr 
in 400 mM Tri-HCl neutralization buffer followed by a 20 min incubation in SYBR green 
I (Sigma-Aldrich, St. Louis, MO). Images were captured using a Nikon Eclipse TE300 
fluorescent microscope. All experiments were replicated using two different sets of 
pooled cultures. The extent of DNA damage was expressed as the comet tail moment (the 
amount and distribution of DNA in the tail). The comet tail moment was measured in a 
minimum of 60 cells using CometScore version 1.5 (TriTek Corp., Sumerduck, VA). 
 
 
Immunohistochemistry 
  
Primary astrocytes were grown on poly-D-lysine chamber slides (BD Bioscience, 
San Jose, CA) for GFAP staining (to confirm astrocyte purity) or on glass coverslips and 
treated with 0 or 10 uM of TG for γH2AX staining. Cells were fixed with 4% PFA/PBS 
for 10 min, permeabilized with 0.5% Triton X-100/PBS for 5 min. Cells were then 
washed with PBS and blocked with 3% BSA/PBS for one hr. Cells were then 
immunostained with either anti-GFAP in PBS (1:500; Sigma-Aldrich, St. Louis, MO) for 
two hr or anti-γH2AX in 3%BSA (1:1000, Millipore Co., Bedford, MA) for one hr. 
Subsequently, cells were washed with PBS and incubated for one hr with Cy2-conjugated 
donkey anti-mouse secondary antibody (1:250 in PBS containing 2% donkey serum and 
0.1% Triton X-100; Jackson Immuno Research Laboratories, West Grove, PA) for GFAP 
or with donkey anti-mouse secondary antibody labeled with 1:800 Alexa 488 in 3% BSA 
(Invitrogen, Carlsbad, CA) for one hr. Finally, vectashield mounting media (Vector 
Laboratories, Burlingame, CA) containing propidium iodide was used to counterstain 
nuclei. Slides were visualized using Nikon Eclipse TE300 fluorescent microscope. Slides 
stained for γH2AX were analyzed for γH2AX foci and a minimum of 100 cells were 
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analyzed per genotype. Cells containing fewer than five foci were excluded to normalize 
for baseline staining observed in control treated cells. Cells with "pan-staining" were 
considered to have more than 5 foci per cell. Hence, the percentage of cells with γH2AX 
foci staining represents the percent of cells with greater than five foci per cell.  
 
 
Statistical Analysis 
 
Differences in cytotoxicity and DNA damage among all three groups were 
compared using Kruskal-Wallis analysis of ranks (Analysis of variance). Mann-Whitney 
U test was used when only two groups were compared. Significance was declared when p 
< 0.05. All statistical analyses were performed using Statistica 8 (StatSoft Inc., Tusla, 
OK). 
 
 
Results  
 
 
Characterization of TPMT +/+, TPMT +/-, and TPMT -/- Primary Mouse Astrocyte 
Cultures 
 
The primary mechanism of thiopurine cytoxicity is believed to be through 
incorportation of TG nucleotide metabolites into DNA [39,152,156] (Figure 3-1), and 
therefore is dependent on the rate of cell proliferation. Hence, we first compared the 
doubling rates between TPMT +/+, TPMT +/-, and TPMT -/- primary astrocyte cultures. 
Primary cultures were established from mouse cortices of each TPMT genotype and 
astrocyte purity was confirmed by GFAP (glial fibrillary acid protein, an astrocyte 
marker) fluorescent staining (Figure 3-3A) [157]. We found that there was no significant 
difference in growth rates of the different TPMT genotypes (Figure 3-3B). The mean 
doubling rates for TPMT +/+, TPMT +/- and TPMT -/- cultures were 33.9, 34.2, and 29.6 
hr, respectively (p = 0.89). Next, we measured the level of TPMT protein activity using a 
well-established radiochemical assay that measures the conversion of 6-mercaptopurine 
to 6-methylmercaptopurine using [14C] S-adenosyl-L-methionine (SAM) as a methyl 
donor [105]. In agreement with previous studies comparing protein activity in 
hematological cells of different TPMT genotypes [121,150,158], protein activities in 
astrocytes were significantly different according to TPMT genotype (Figure 3-3C). 
TPMT +/+, TPMT +/-, and TPMT -/- primary astrocytes displayed high (7.6 unit/109μg 
protein), intermediate (3.9 unit/109 μg protein), and low (0.25 unit/109 μg protein) levels 
of protein activity, respectively (p = 0.018). Based on these data, we next determined 
whether TPMT could modulate the cytotoxic effects of TG in primary astrocytes. 
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Figure 3-3. Characterization of TPMT +/+, TPMT +/-, and TPMT -/- primary 
astrocyte cultures. 
 
A, The image (200x) of primary astrocytes showing high astrocyte purity determined by 
GFAP (green) and propidium iodide (red) fluorescent staining. B, There was no 
significant difference in growth rates between astrocyte cultures of each TPMT genotype 
(p = 0.89). C, The level of TPMT protein activity was significantly different between the 
three TPMT genotypes (p = 0.018); and levels were comparable to Nalm6 and CEM 
control lymphoblastoid cell lines. Bars represent the means; whiskers represent the 
standard deviation (±); * p < 0.05. Adapted with permission from Hosni-Ahmed A, 
Barnes JD, Wan J, Jones TS (2011) Thiopurine methyltransferase predicts the extent of 
cytotoxicty and DNA damage in astroglial cells after thioguanine exposure. PLoS ONE 
6: e29163. 
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Comparison of TG-Associated Cytotoxicity in TPMT +/+, TPMT +/-, and 
TPMT -/- Primary Astrocyte Cultures 
 
To determine whether TPMT could predict thiopurine cytotoxicity in primary 
astrocytes, the MTT colorimetric assay was employed to compare TG sensitivity between 
astrocytes of each TPMT genotype. This assay measures cell viability by quantitating the 
extent at which metabolically active cells can reduce tetrazolium salt (MTT) to form 
purple formazan crystals. Astrocytes were exposed to escalating concentrations of TG 
(0.125, 1.25, 12.5, 25, 50, and 100 μM) for five days and then subjected to the MTT 
assay. Cell viability data at each TG concentration was used to calculate IC50 values. As 
expected, TG treatment resulted in cytotoxicity in a dose dependant manner (Figure 
3-4A). Cell viability was significantly lower in TPMT +/- and TPMT -/- cultures at four 
concentrations of TG (12.5, 25, 50, and 100 μM) when compared to TPMT +/+ cultures (p 
< 0.04). Interestingly, TPMT +/- but not TPMT -/- astrocytes were significantly more 
sensitive at 1.25 μM of TG than TPMT +/+ astrocytes (p = 0.004); and this finding was 
reflected in corresponding IC50 values. There was a 2.9 fold reduction in IC50 in TPMT +/- 
(3.5 μM TG) versus a 1.2 fold reduction in TPMT -/- (8.6 μM TG) when compared TPMT 
+/+ astrocytes (10.3 μM TG); and the TPMT +/- and TPMT -/- IC50 values were 
significantly different from TPMT +/+ (p < 0.05) (Figure 3-4B). Studies have shown that 
genotoxicity (i.e. DNA strand breaks) correlates with cytotoxicity after TG exposure 
[116,156]. Hence, we investigated whether the degree of TG-induced DNA strand breaks 
was associated with the level of cytotoxicity in primary astrocytes.  
 
 
Comparison of the Extent of DNA Damage Between TPMT +/+, TPMT +/-, and 
TPMT -/- Primary Astrocytes 
 
To address the question of whether the level of TG-induced cytotoxicity is 
correlated with DNA damage, we employed the alkaline comet assay. This assay 
quantifies DNA damage [i.e. single strand breaks (SSBs), double strand breaks (DSBs) 
and alkali labile sites] using fluorescent microscopy to visualize the extent of DNA 
migration from the nucleus of individual cells embedded in agarose [159]. We exposed 
astrocytes to 5 μM of TG for 72 hr. IC50 data was used to select a dose that would allow 
us to capture damage in each genotype. We observed a significant difference in DNA 
damage between the three genotypes as measured by mean comet tail moment. Both 
TPMT +/- and TPMT -/- astrocytes had a significantly greater degree of DNA damage than 
TPMT +/+ astrocytes (mean comet tail moment = 2.64, 1.26, and 0.4, respectively; p = 
0.033) (Figure 3-5A). In agreement with MTT studies, TPMT +/- astrocytes were more 
sensitive to TG, as evidenced by a greater degree of DNA damage, than were TPMT -/- 
astrocytes. The difference in DNA damage between TPMT +/- and TPMT -/- astrocytes 
was not significantly different (p = 0.083). There was no difference in DNA damage 
between TPMT genotypes of control treated astrocytes.  
 
Studies have shown that the predominant DNA lesions caused by TG are SSBs 
although some DSB lesions are formed [156]. Therefore, we then compared γH2AX (an 
established DSB marker) foci staining after TG exposure to determine the extent of the  
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Figure 3-4. Comparison of TG-induced cytotoxicity in primary astrocyte cultures 
of each TPMT genotype.  
 
A, Primary astrocytes of each TPMT genotype were exposed to thioguanine (TG) and 
cell viability was determined using the MTT assay. TPMT +/- and TPMT -/- astrocytes 
were significantly more sensitive to TG (12.5 - 100µM) than TPMT +/+ (p < 0.04). B, IC50 
values were significantly different between the three genotypes (p = 0.027) and TPMT +/- 
astrocytes were the most sensitive. Bars represent the means; whiskers represent the 
standard deviation (±); * p < 0.05. Adapted with permission from Hosni-Ahmed A, 
Barnes JD, Wan J, Jones TS (2011) Thiopurine methyltransferase predicts the extent of 
cytotoxicty and DNA damage in astroglial cells after thioguanine exposure. PLoS ONE 
6: e29163.  
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Figure 3-5. Comparison of TG-induced genotoxicity in primary astrocyte cultures 
of each TPMT genotype.  
 
A, The alkaline comet assay was used to compare TG-induced DNA damage between 
TPMT genotypes. TPMT +/- and TPMT -/- astrocytes had significantly higher mean comet 
tail moments than TPMT +/+ astrocytes (p = 0.033). B, Immunoflourescence staining for 
γH2AX confirms IC50 and comet data. TPMT +/- astrocytes had greater damage than 
TPMT +/+(p = 0.03).  Below are representative images of γH2AX staining for control 
treated (left) and TG treated (right) astrocytes. γH2AX foci stained in green; nuclei 
stained in red (Zeiss LSM 710 Laser Scanning Microscope, 400x magnification). Bars 
represent the means; whiskers represent the standard deviation (±); * p < 0.05. Adapted 
with permission from Hosni-Ahmed A, Barnes JD, Wan J, Jones TS (2011) Thiopurine 
methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells 
after thioguanine exposure. PLoS ONE 6: e29163. 
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DNA lesions that are in the form of DSBs and whether this damage is different between 
the TPMT genotypes. Astrocytes were seeded on glass coverslips and exposed to either 0 
or 5μM of TG. We found that TPMT +/- astrocytes had the greatest degree of γH2AX foci 
staining (19.4%) compared to TPMT +/+ (9.3%), and TPMT -/- (7.22%) (Figure 3-5B). In 
agreement with comet data, TPMT +/- was the most sensitive genotype. There was a 
significant difference between TPMT +/- and TPMT +/+ (p = 0.03), but no significant 
difference was observed between TPMT -/- and TPMT +/+ cells. 
 
 
Comparison of TG Phenotypes Between Human Glioma Cell Lines with Different 
TPMT Protein Activities  
 
Next, we conducted conducted MTT and comet assays to assess TG-induced 
cytotoxicity and genotoxicity in human glioma cell lines with high and low TPMT 
activity and compared TG-induced cytotoxicity and DNA damage between them. First, 
we measured TPMT protein activity in four human glioma cell lines (T98, A172, U87, 
and LN18) to identify high and low TPMT expressers. We chose T98 (10.48 unit/109 μg 
protein) and A172 (6.15 unit/109 μg protein) as the high and low expressers, respectively 
(Figure 3-6A). We then subjected T98 and A172 to the MTT assay to measure 
TG-induced cytotoxicity. Both cell lines were exposed to increasing concentrations of TG 
(0.15, 0.75, 1.5, 6.25, 12.5 and 25 μM) for five days. The cell viability was determined 
for each concentration and these data were used to calculate IC50 values. As predicted by 
TPMT activity and in agreement with MTT studies performed in primary astrocytes, 
A172, the low TPMT expressing cell line, had significantly lower cell viabilities at each 
TG concentration as compared to T98 (p < 0.005) (Figure 3-6B). The higher TG 
sensitivity of A172 was also reflected in the IC50 values. A172 displayed a 6.9 fold lower 
IC50 (1.2 μM) when compared to T98 (8.3 μM) (Figure 3-6C).  
 
Next, we employed the comet assay to compare DNA damage between T98 and 
A172 cultures exposed to 3μM TG for 72 hr. In agreement with the primary astrocyte 
data, cells with low level of TPMT activity had significantly more DNA damage 
compared to high TPMT activity (mean comet tail moment: A172 = 1, T98 = 0.3; p = 
0.02) (Figure 3-6D). DNA damage in control treated cells was not significantly different 
between the two cell lines.  
 
 
Comparison of TG Phenotypes Between A172mock and A172TPMT Isogenic Cell Lines 
 
To further validate our findings, TG-induced toxicity was compared using 
isogenic cell lines with different TPMT activities. A172 cells were the lowest TPMT 
expresser, hence we over-expressed TPMT protein in this cell line using lentiviral vector 
and compared TG-induced cytotoxicity and DNA damage between the mock transduced 
(A172mock) and TPMT transduced (A172TPMT) cell lines. Transduction efficiency was 
monitored by GFP expression (Figure 3-7A). In addition, the level of TPMT protein 
activity in A172TPMT was significantly higher as compared to A172mock (151.23 unit/109 
μg protein versus 9.47 unit/109 μg protein, respectively; p < 0.05) (Figure 3-7B). We  
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Figure 3-6. Assessment of TPMT-associated phenotypes in human glioma cell 
lines. 
 
TPMT protein activity was measured in T98 and A172 glioma cell lines. A, T98 
displayed a significantly higher level of protein activity than A172 (p < 0.05). B, As 
observed in primary astrocyte cultures, low TPMT protein activity is associated with 
greater cytotoxicity as determined by the MTT assay; C, and reflected in IC50 values. 
A172 cells had a significantly more sensitive at all TG concentrations and lower IC50 than 
T98 (p < 0.05). D, The alkaline comet assay was used to compare TG-induced DNA 
damage. A172 displayed a significantly greater degree of TG-induced DNA strand breaks 
than T98 (p = 0.02) as measured by mean comet tail moment. Bars represent the means; 
whiskers represent the standard deviation (±); * p < 0.05. Adapted with permission from 
Hosni-Ahmed A, Barnes JD, Wan J, Jones TS (2011) Thiopurine methyltransferase 
predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine 
exposure. PLoS ONE 6: e29163. 
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Figure 3-7. TPMT-associated phenotypes in A172 isogenic cells. 
 
TPMT was overexpressed in A172 cells using lentivial vector. A, Transduction efficiency 
was monitored by GFP expression. B, TPMT protein activity was measured in A172mock 
and A172TPMT cell lines. TPMT protein activity was significantly higher in A172TPMT (p 
< 0.05). C, There were no significant differences in doubling times between A172TPMT 
and A172mock (p = 0.38). D, A172TPMT showed a significantly higher resistance to 
TG-induced toxicity when compared to A172mock as determined by the MTT cell viability 
data (p < 0.005) and E, by IC50 values (p < 0.05). F, The alkaline comet assay was used 
to compare TG-induced DNA damage. A172mock displayed a significantly higher DNA 
damage than A172TPMT (p = 0.03) as measured by mean comet tail moment. Bars 
represent the means; whiskers represent the standard deviation (±). * p < 0.05. Adapted 
with permission from Hosni-Ahmed A, Barnes JD, Wan J, Jones TS (2011) Thiopurine 
methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells 
after thioguanine exposure. PLoS ONE 6: e29163. 
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Figure 3-7. Continued. 
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performed growth rate studies and found that there were no difference in doubling times 
between A172TPMT and A172mock (28.5 and 29.6 hr, respectively; p = 0.38) (Figure 
3-7C). When A172mock and A172TPMT were exposed to increasing concentrations of TG 
we found that A172mock had significantly lower cell viabilities at 0.75, 1.5, 6.25, 12.5 and 
25 μM of TG as compared to A172TPMT (p < 0.005) (Figure 3-7D). These findings were 
reflected in the A172TPMT IC50 value that was approximately two-fold higher than 
A172mock (3.9 μM versus 1.9 μM, respectively; p < 0.05) (Figure 3-7E).  
 
Next, we exposed A172TPMT and A172mock to 5 μM of TG for 72 hr and compared 
the extent of DNA damage using the comet assay. We selected 5 μM based on the IC50 
value of A172TPMT. As expected, A172mock had a significantly greater degree of DNA 
damage when compared to A172TPMT (mean comet tail moment: A172mock = 0.7, 
A172TPMT = 0.24; p = 0.03) (Figure 3-7F). DNA damage in control treated cells was not 
significantly different between the two cell lines (p = 0.35). These data support our 
findings observed in both the primary mouse astrocytes and the glioma cell lines (T98 
and wild-type A172) that when TPMT protein activity is low a greater degree of 
cytotoxicity and DNA damage can occur after TG exposure.  
 
 
Discussion 
 
TPMT is a cytoplasmic enzyme responsible for deactivating thiopurine drugs and 
a low TPMT phenotype can lead to life-threatening hematological toxicities when 
thiopurines are given. Indeed, chronic administration of thiopurines has been linked to an 
increased risk of cancer including brain tumors [47,48,50,52,67]. Unfortunately, not all 
patient populations that are treated with thiopurines are evaluated for their TPMT status 
prior to initiating thiopurine therapy; hence, the importance of TPMT to 
thiopurine-associated cancer risk is not clear. Since TPMT deficiency is relatively rare 
across populations, it is difficult to assess the importance of TPMT status to thiopurine 
therapy-related cancer risk. However, in a report by Relling et al. it was shown that 
whether patients developed a brain tumor as a late complication of post-antileukemic 
therapy depended on their TPMT status [47]. Patients who were determined to be at high 
risk for treatment relapse received prophylactic cranial irradiation concurrent with 
antimetabolite therapy; and those patients with a low TPMT had a surprisingly high 
incidence of brain tumors as a late complication. Indeed, ionizing radiation is a risk factor 
for brain tumorigenesis. However, in this report, patients with low TPMT had a 42.9% 
incidence of brain tumors compared to 15.8% for those with high TPMT.  
 
Astrocytomas are the most common brain tumor type that has been reported in 
patients after thiopurine therapy [47,48,50,67]. To our knowledge, the importance of 
TPMT status to thiopurine-associated phenotypes in astroglial cells has not been 
investigated. We assessed TPMT and TG phenotypes in astroglial cells using primary 
mouse astrocytes from different TPMT genotypes and human glioma cells that differ in  
TPMT activity. In this study we have shown that TG induces cytotoxicity in a 
dose-dependent manner in astroglial cells; and cells with a low TPMT phenotype 
(TPMT+/- and TPMT -/- astrocytes and A172mock) were significantly more sensitive to TG. 
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We also showed that TG exposure induced more DNA damage in the form of SSBs in 
astroglial cells with low TPMT than in cells with high TPMT. DNA damage in the form 
of DSBs was significantly different between astroglial cells with low and high TPMT. 
SSBs have been shown to be the primary DNA lesion induced by thiopurine drugs [156].  
 
Interestingly, we found that low but not the complete absence of TPMT sensitized 
primary astrocytes to a higher degree of cytotoxicity and genotoxicity (i.e. IC50, SSBs and 
DSBs) after TG exposure. This discordance could possibly be explained by the induction 
of a compensatory mechanism that deactivates thiopurines upon the complete loss of 
TPMT. Another possible explanation could be a defect in the mismatch repair (MMR) 
system's ability to recognize DNA-TG nucleotide lesions. The MMR system is 
responsible for recognizing DNA mis-pairing caused by DNA-TG nucleotides and the 
subsequent signaling for cell death [160-163]. The latter possibility suggests that 
astroglial cells with a defective TPMT activity could have DNA lesions persisting in the 
genome that could potentially lead to mutagenesis and cancer. Interestingly, some studies 
suggest that children with TPMT heterozygosity develop brain tumors and other cancers 
more frequently than children with mutant TPMT. However, the frequency of 
heterozygous or mutant TPMT is very low making it is difficult to make any definitive 
conclusions [47,164]. It would be interesting to investigate whether TPMT status 
influences the extent of TG nucleotide incorporation into DNA and damage recognition 
by the MMR system as well as whether ionizing irradiation alone or in combination with 
thiopurines results in similar findings.  
 
In summary, chronic thiopurine therapy has been associated with the development 
of brain cancer and TPMT status has been linked to brain tumor risk. We found that 
TPMT is an important factor for thiopurine drug-induced cytotoxicity and genotoxicity in 
astroglial cells. Because of the limited availability of human astrocytes we used human 
glioma cell lines. Although glioma cells can exhibit a number of genetic alternations that 
could contribute to the phenotypes observed, our study shows that TPMT is indeed an 
important determinant of thiopurine toxicity.  
 
Low TPMT can increase the level of TG-induced genotoxic damage in both 
normal and in neoplastic astroglial cells. The observation that glioma cells can have 
variable degrees of TPMT protein activity and that low protein activity can sensitize cells 
to TG may suggest that thiopurines may potentially have a therapeutic role in low TPMT 
expressing glial tumors. However, since thiopurine drugs are linked with secondary brain 
tumors, we do not recommend the use of these agents in brain tumor treatment. 
Furthermore, In vitro studies have shown that thiopurine drugs are associated with 
mutagenic events in a variety of cell lines [116,151]. It is possible that the DNA damage 
caused by low TPMT function can ultimately contribute to transformative events over 
time. One study found that TPMT was not an important factor for cancer risk after 
thiopurine therapy [164]; however in this study only TPMT genotype was determined 
which may have excluded patients with discordance between TPMT genotype and 
activity. Individuals who are wild-type for TPMT can display a wide variation in their 
TPMT activity [127]. Further studies are needed to understand the importance of TPMT 
in the brain when thiopurines are given. Whether these findings can be replicated in vivo 
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and whether factors important to DNA repair mechanisms are responsible for the TG 
phenotypes described in this study should also be investigated.  
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CHAPTER 4.    SCREENING OF NOVEL ANTI-GLIOMA SMALL 
MOLECULES* 
 
 
Introduction 
 
 
Significance of Glioma Disease 
 
According to CBTRUS report, gliomas represent 80% of the malignant brain 
tumor incidence in the United States [2]. Furthermore, the overall survival rate is 3 years 
for less than 8% for grade IV GBM. On the global scale, the incidence of malignant brain 
tumors is approximately 3 in 100,000 per year, with a higher rate in the developed 
countries compared to the developing countries [4,5]. GBM is the most aggressive 
subtype of brain tumor and is characterized by diffuse infiltration into normal brain 
parenchyma making its resection very challenging. Consequently, these tumors can 
repopulate after surgery, causing cancer relapse [3]. Typical treatment involves surgical 
resection followed by cranial irradiation, which can alleviate the neurological symptoms 
and seizures in glioma patients. In general, patients receive 54-60 Gy radiotherapy 
regimen in 30 fractions during 6 weeks of treatment [3]. Usually concurrent TMZ therapy 
of 75 mg /m2/day is given during the irradiation therapy followed by 28 cycles of 
adjuvant TMZ therapy (150 mg/m2/day for 5 days/ week). Despite this aggressive 
therapy, there has not been a significant improvement in either the prognosis or the 
survival of patients. Therefore, there is an urgent need to find new therapeutical 
approaches to improve patients’ survival and outcome. The current study focused on 
assessing the potential anti-cancer activity of 2 classes of small molecules; 
tetrahydroisoquinoline (THIQ) and chromene derivatives. A series of in vitro studies 
were conducted as part of the screening process to find the most potent derivatives with 
least toxicity to normal stromal cells. 
 
 
Tetrahydroisoquinoline Derivatives 
 
The laboratory of Dr. Duane Miller at UTHSC focuses on the synthesis of novel 
compounds against a wide variety of diseases and disorders including gliomas. In 2006, 
Mohler et al. have discovered novel THIQ derivatives that reduced cell viability in a rat 
glioma cell model [165]. According to this study, compound 1 (EDL-155) was the most 
toxic analog in glioma as well as lung, breast and cervical cancer cell lines. The IC50 
values ranged from approximately 3-10 μM, depending on the cancer cell line. Therefore,  
 
 
------------------------------------ 
*Adapted with permission. Patil R, Hosni-Ahmed A, Jones T, Patil S, Asres L, et al. (2014) 
Synthesis and In Vitro Evaluation of Novel 1,2,3,4-Tetrahydroisoquinoline Derivatives as Potent 
Antiglioma Agents. Anticancer Agents Med Chem (In Press). Patil SA, Wang J, Li XS, Chen J, 
Jones TS, et al. (2012) New substituted 4H-chromenes as anticancer agents. Bioorg Med Chem 
Lett 22: 4458-4461. 
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we were interested in investigating the anti-cancer activity of other THIQ analogs in a 
panel of human glioma cell lines [166].  
 
 
Chromene Derivatives 
 
One of the limiting factors of cancer therapeutics is poor drug penetration. 
Previous studies showed an improvement in drug penetration as well as efficacy when 
Arginine-Glycine-Aspartic Acid (RGD) peptides were co-injected with anti-cancer drugs 
[167]. Drs. Miller and Patil research groups used RGD and similar analogs to search 
online libraries for similar anti-tumor small molecules [168]. From the 2 hits obtained, 
GRI-394837, a chromene analog was subsequently investigated. Chromenes are analogs 
of podophyllotoxin, a natural plant product, that have been isolated from Podophyllum 
species [169]. Whereas, podophyllotoxin function in plants is not fully understood, its 
semisynthetic analogs exhibit anti-cancer activity. Chromenes demonstrated high 
efficiency as apoptosis inducers by inhibiting microtubule assembly and as vascular 
disrupting agents (VDA) [170,171]. In the current study, several chromene derivatives 
have been synthesized and their activities in glioma were assessed in vitro and in vivo. 
 
 
Materials and Methods 
 
 
Drug Preparation 
 
THIQ and chromene small molecules have been synthesized in Dr. Miller and Dr. 
Patil’s laboratories respectively at UTHSC. For in vitro screening, a freshly prepared 50 
μM stock solution was prepared by dissolving EDL-360 in DMSO. EDL-291 was 
dissolved in PBS to prepare 10μM stock solution. Other THIQs, chromenes and TMZ 
compounds were dissolved in DMSO. A freshly prepared 100 μL stock solution was 
prepared by dissolving the compound in DMSO. For treatment of tumor-bearing mice, 
EDL-360 was dissolved in 0.9% saline, whereas SP-6-27 was dissolved in glacial acetic 
acid. 
 
 
Glioma Cell Lines and Primary Astrocyte Cultures 
 
The human glioma cell lines, T98, U87 and LN18, were obtained from the 
American Type Culture Collection (Manassas, VA, USA). A172 glioma culture was a 
generous gift from Dr. C. Duntsch (Department of Neurosurgery, UTHSC). T98 and U87 
cultures were grown in Minimum Essential Medium Eagle (Cellgro, Hemdon, VA), 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 0.1 mM nonessential 
amino acids, 1 mM sodium pyruvate, 100 IU/ml penicillin, and 100 μg/ml streptomycin. 
A172 cells were grown in Dulbecco’s Modified Eagle’s Medium (Cellgro, Hemdon, 
VA), supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU/ml 
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penicillin, and 100 μg/ml streptomycin. All cell cultures were maintained at 37°C in a 5% 
CO2 humidified atmosphere. 
 
Astrocyte cultures were established from 2-5 day old mice. A dissecting 
microscope was used to remove the meninges and hippocampus, and the cortices were 
mechanically dissociated. Subsequently, cultures were established and maintained in 
Dulbecco’s modified Eagle’s medium/Ham's F-12 50/50 mix (Cellgro, Hemdon, VA) 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU/ml penicillin, 
100 μg/ml streptomycin and 20 ng/ml epidermal growth factor (Millipore Co., Bedford, 
MA) and grown in Primaria flasks, (BD Bioscience, San Jose, CA). After three days of 
incubation, cultures were fed with 20 ng/ml epidermal growth factor and the media was 
changed after five days. At passage 2 three individual primary cultures of the same 
genotype were pooled and seeded for experiments. Only cultures with greater than 80% 
astrocyte purity as determined by GFAP immunohistochemistry were included in 
experiments.  
 
 
MTT Assay 
 
Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, MO). In brief, 1000 cells were 
seeded per well in 96-well plates. Plates were pre-coated with poly-L-ornithine 
(Sigma-Aldrich, St. Louis, MO) and laminin (Invitrogen, Carlsbad, CA) for primary 
astrocytes to facilitate cell attachment. Cells were allowed to attach overnight and small 
molecules or vehicle control was added to the appropriate wells. After five days, MTT 
was added and allowed to incubate for 3 hr. The media was carefully aspirated and the 
purple formazan crystals were dissolved in 100 μl DMSO (Fisher Scientific Co., Fair 
Lawn, NJ). Absorbance was measured at 570/690 nm using a FLx800 fluorescence 
microplate reader (BioTek Instruments, Inc., Burlington, VT). A series of experiments 
were conducted to determine the concentration range for each compound to generate a 
half-maximal inhibitory concentration (IC50).  
 
 
Lentiviral Transduction 
 
Luciferase cDNA was amplified by PCR, purified through agarose gel 
electrophoresis, and subcloned into BamHI and EcoRI sites of pLenti-pgk-puro vector 
(Viral vector core, UTHSC) (Figure 4-1A). The pLenti-Luc-mKate-pgk-puro and 
pLenti-pgk-puro lentiviral vectors were packaged in 293T cells [154]. The lentiviral 
vectors were used to transduce the U87 glioma cell line in the presence of 6 μg/mL 
polybrene (Sigma-Aldrich, St. Louis, MO) (Figure 4-1B). Stably transfected cells were 
then selected by growing the cells in 1 μg/ml puromycin. Transduction efficiency was 
monitored by using fluorescent microscope. 
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Figure 4-1. pLenti-pgk viral vector. 
 
A, Luciferase and mkate cDNA were subcloned into pLenti-pgk-puro vector using 
BamHI and EcoRI sites. B, The lentivial vectors were packaged in 293T cells. The 
mock- (U87mock) and Luciferase-transduced (U87Luc) cell lines were generated by 
transducing U87 cells with either pLenti-Luc-mkate-pgk-puro or pLenti-pgk-puro 
lentivial vector (empty vector), respectively. 
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Luciferase Activity 
 
Luciferase activity was measured in U87 transduced cells using dual-luciferase 
reporter assay (Promega, Madison, WI). U87Luc and U87mock were seeded in 6-well plates 
and allowed to reach 70% confluency. After removing cell medium and washing once 
with PBS, the cells were lysed in 500 μL 1X passive lysis buffer (PLB) for 15 min at 
room temperature with gentle shaking. Subsequently, 10 μL of PLB lysate was mixed 
with 50 μL LARII (luciferase substrate) and firefly luciferase activity was determined 
using GloMax- Multi Jr Single-Tube Multimode Reader (Promega, Madison, WI). 
 
 
In Vivo Drug Testing  
 
A glioma xenograft mouse model was generated by injecting U87Luc cells 
subcutaneously in 4-6 week old NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (Jackson 
Laboratory, Bar Harbor, ME. The mice were anesthetized using isoflurane and 
subcutaneously injected with 100 μL containing 107 U87Luc cells in the right flank of the 
mice. Once the tumors were palpable, the mice were divided randomly into groups of 5 
mice (i.e. untreated, vehicle treated, and drug treated). Subsequently, 100 μL of the test 
compounds were administered intratumorally. Tumor size, body weight and 
bioluminescence signal were obtained twice/week. In addition, non-invasive 
bioluminescent imaging was acquired biweekly using the IVIS-200 Imaging System 
(Xenogen Corporation, Berkeley, CA). The studies were terminated when the tumors 
reached 10% of total body weight.  
 
 
Statistical Analysis 
 
Mann-Whitney U test was used when only two groups were compared. The 
results were considered significant when p < 0.05. All statistical analyses were performed 
using Statistica 8 (StatSoft Inc., Tusla, OK).  
 
 
Results 
 
 
In Vitro Screening of THIQ Analogs 
 
The anti-cancer activity of THIQ analogs in human glioma cell lines was 
investigated in vitro using MTT cell viability assays. In order to determine whether the 
compounds had toxicity in normal brain cells, astrocyte cultures were generated from the 
cortex of normal mice. Both glioma and astrocytes cultures were plated and treated under 
the same conditions. A series of MTT assay were performed to find the dosing range for 
each compound to calculate the IC50 values. 
TMZ is the standard chemotherapy for treating glioma and was used in the current 
study as a reference to evaluate the anti-cancer efficacy of our compounds. T98, U87, 
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LN18 and A172 glioma cell lines were more sensitive to TMZ compared to normal 
astrocytes (Figure 4-2A). At a concentration 1000 µM, TMZ did not induce 50% death 
of normal astrocytes. T98 and LN18 cells were more resistant to TMZ compared to U87 
and A172 cells. When glioma cell lines were treated with THIQ compounds, cell death 
was induced in a dose dependent manner. EDL-155 was very potent against glioma cell 
lines induced ~ 95% cell death at 20 µM (Figure 4-2B). However, it was quite toxic to 
normal astrocytes as well (IC50 = 5.2 µM). LN18 was the only cell line that EDL-155 
markedly inhibited cell viability at all the concentrations tested and had a significantly 
lower IC50 compared to astrocytes (p < 0.05). EDL-323 was significantly more toxic to 
LN18 and A172 cells than normal astrocytes (p < 0.05) and completely inhibiting their 
viability at 80 µM (Figure 4-2C). Similar to EDL-323, EDL-291 analog significantly 
reduced the viability of LN18 and A172 cells (IC50 = 37 and 41.2 µM, respectively) 
compared to normal astrocytes (IC50  = 51.1 µM) (p < 0.05) (Figure 4-2D). EDL-355 
showed better anti-cancer activity compared to EDL-291 and EDL-323 (Figure 4-2E). It 
had significantly lower IC50 value in LN18 cells (IC50 = 7.3 µM) compared to normal 
astrocytes (IC50 = 10.3 µM). However, EDL-358 was more selective toxicityto glioma 
cell lines (Figure 4-2F). It had a significantly higher IC50 in normal astrocytes compared 
to all glioma cell lines (p < 0.05). EDL-360 showed a higher cytotoxic action in glioma 
cell lines (IC50 = 5.4- 10,4) µM compared to EDL-358 (IC50 = 8.25- 24.6). In addition, it 
significantly induced cell death in all glioma cell lines compared to normal astrocytes (p 
< 0.05) (Figure 4-2G). Further modification in EDL-361 resulted in an increased toxicity 
in normal astrocytes, and hence a decrease in selective toxicity for glioma cell lines 
(Figure 4-2H).  
 
 
In Vitro Screening of Chromene Analogs 
 
Next, we assessed the anti-glioma toxicity of chromene analogs in vitro. MTT cell 
viability assay showed high anti-glioma activity of SP-6-19. Greater than 90% of glioma 
cells were dead at a 10 µM concentration, whereas the same dose killed < 50% of normal 
astrocyte cells (Figure 4-3A). The observed cytotoxicity in glioma cell lines was in 
nanomolar range (IC50 < 80 nM). In contrast, a concentration of 9.5 µM was required to 
reach an IC50 in normal astrocytes. It appeared to be most toxic in A172 cell line 
compared to LN18 and U87 cells. SP-6-21 was less toxic compared to SP-6-19. 
However, the observed cytotoxicity remained in the submicromolar range in glioma cell 
lines (Figure 4-3B). All the test glioma cell lines appear to respond equally to the toxic 
action of this analog. SP-6-23 exhibited even less toxicity compared to SP-6-21. IC50 
values ranged from 0.7-0.9 µM in all glioma cell lines (Figure 4-3C). Approximately, 
90% cell death was observed in T98 and U87 cells at 20 μM, whereas, in LN18 and A172 
was ~5% at the same concentration. Chromene analog, SP-6-25, exerts anti-glioma 
activity in micromolar range (~1.2 μM) (Figure 4-3D). Interestingly, astrocytic cell death 
was only observed at the 100 μM concentration. Approximately, a 60-fold higher 
concentration is needed to reach IC50 in normal astrocytes. Interestingly, SP-6-27 was the 
most potent chromene analog (Figure 4-3E). There was an approximately 90% reduction 
of glioma cell viability at 0.1 µM, while in astrocytes the IC50 was ~ 2 µM. All tested 
glioma cell lines had a significantly lower IC50 values compared to normal astrocytes (P < ?
 65 
Figure 4-2. The effect of THIQ analogs and TMZ on the cell viability of gliomas 
and astrocytes. 
 
A, The glioma cell lines were more sensitive to TMZ compared to normal astrocytes. B, 
THI analog; EDL-155 was more toxic to both normal astrocytes and human glioma cell 
lines compared to TMZ. C, EDL-323 derivative showed less potency against glioma cell 
lines when compared to EDL-155. However, LN18 and A172 had a significant less 
viabilities and IC50 compared to normal astrocytes. D, EDL-291 analog exhibited a 
similar activity profile to EDL-323 in terms of toxicity and selectivity. E, Methoxy 
meta-substitution (EDL-355) enhanced the toxicity, however the selectivity remained 
poor. F, Methoxy para-substitution (EDL-358) had similar toxicity pattern against glioma 
lines compared to EDL-155. More importantly, EDL-358 had a significant higher IC50 in 
normal astrocytes compared to for all glioma cell lines. G, Adding one carbon atom to 
the carbon linker between biphenyl and THI ring (EDL-360; n = 1) improved both 
toxicity and selectivity of EDL-360 analog. H, Further increasing the length of the 
carbon linker (EDL-361; n = 2) reduced the toxicity against glioma cell lines when 
compared to EDL-360 and showed almost equal potency to normal astrocytes. MTT cell 
viability using escalated doses of the test compounds (left panels). Bar graphs comparing 
the IC50 data for normal mouse astrocytes and human glioma cell lines (right panels). 
Bars represent the means; whiskers represent the standard deviation (±), *p < 0.05. 
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Figure 4-2.  Continued.  
 68 
 
 
 
 
 
Figure 4-2.  Continued.  
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Figure 4-2.  Continued.  
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Figure 4-3. The effect of chromene analogs on the cell viability of glioma and 
astrocytes. 
 
A, LN18, U87 and A172 had significantly lower IC50 values for SP-6-19 compared to 
normal astrocytes. B, SP-6-21 was less toxic compared to SP-6-19. However, the 
observed cytotoxicity remained in the submicromolar range in glioma cell lines. C, 
SP-6-23 exhibited even less toxicity compared to SP-6-21. D, Chromene analog, 
SP-6-25, exerts anti-glioma activity in micromolar range. Interestingly, astrocytes were 
quite insensitive to its cytotoxicity. E, SP-6-27 showed an enhanced activity and 
selectivity. All tested glioma cell lines had significantly lower IC50 values compared to 
normal astrocytes. F, SP-6-35 appeared to be less active compared to SP-6-27 and it 
selectively induced cell death in T98 and LN18 compared to U87 and A172. G, 
Similarly, SP-6-37 exhibited a selective toxicity in LN18 and A172 compared to T98 and 
U87. Up to 100 µM of SP-6-37 did not cause significant cell death in astrocytes. H, 
There is a large decrease in SP-6-41 activity compare to any other chromene compound 
tested thus far. However, it was not quite toxic to astrocytes compared to glioma cell 
lines. I, SP-6-43 showed a slightly higher anti-glioma effect compared to SP-6-41. MTT 
cell viability using escalated doses of the test compounds (left panels). Bar graphs 
comparing the IC50 data for normal mouse astrocytes and human glioma cell lines (right 
panels). Bars represent the means; whiskers represent the standard deviation (±), *p < 
0.05. Adapted with permission from Patil R, Hosni-Ahmed A, Jones T, Patil S, Asres L, 
et al. (2014) Synthesis and In Vitro Evaluation of Novel 1,2,3,4-Tetrahydroisoquinoline 
Derivatives as Potent Antiglioma Agents. Anticancer Agents Med Chem (In Press). 
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Figure 4-3.  Continued.  
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Figure 4-3.  Continued. 
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Figure 4-3.  Continued. 
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Figure 4-3.  Continued. 
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0.05). In contrast, SP-6-35 had a much lower activity compared to SP-6-27 (Figure 
4-3F).  SP-6-35 selectively induced cell death in T98 and LN18 cells compared to U87 
and A172 cells. The IC50 values ranged from 1-3 µM in glioma cell lines, and it was 
approximately 90 µM in normal mouse astrocytes. Similarly, SP-6-37 exhibited selective 
toxicity in LN18 and A172 compared to T98 and U87 cells (Figure 4-3G). Up to 100 µM 
of SP-6-37 did not cause significant cell death in astrocytes. There is a large decrease in 
SP-6-41 and SP-6-43 activity compared to any other chromene compounds tested thus far 
(Figure 4-3H and Figure 4-3I). However, it was not as quite toxic in astrocytes as 
compared to glioma cell lines. Astrocytes had a higher viability at 1, 5, 10, 50 and 100 
µM of SP-6-41 and the IC50 in astrocytes was significantly higher than on glioma cell 
lines. Finally, SP-6-43 showed a slightly higher anti-glioma effect compared to SP-6-41. 
The IC50 value for glioma cell lines ranged from 6 to 15 µM, whereas in astrocytes it was 
> 100 µM. 
 
 
Effect of EDL-360 in Human Glioma Xenograft Mouse Model  
 
Based on in vitro screening results, EDL-360 was found to be the most potent 
THIQ analog. To assess its anti-glioma activity in vivo, mice bearing U87 glioma 
xenografts were treated with a daily single dose of EDL-360, and tumor engraftment 
examined by caliper and xenogen animal imaging. For bioluminescence imaging, U87 
glioma cell line was transduced with the pLenti-Luc-mKate-pgk-puro viral vector, and 
the cells were grown in puromycin to select stably transfected cells. Luciferase activity 
was measured in U87luc and U87mock cultures using dual-luciferase reporter assay. Mean 
luciferase luminescence was 1.79 X107/8.3 X 105 cells (± 6.4X105) and 173/7.8 X 105 
cells (± 19) relative light units (RLU) in U87luc and U87mock, respectively. To generate the 
glioma mouse model, U87luc cells were injected subcutaneously into the right flank of 4-6 
week old BALBc (NSG) mice. Once the tumor became palpable the mice were randomly 
assigned into groups of 5 mice. The treated group received 5 μM of EDL-360 daily, 
whereas the control group did not receive any treatment. Mice were monitored daily for 
any signs or symptoms of drug related toxicity. In addition, mice were weighed twice a 
week. There was no sign of toxicity or weight loss in the EDL-360 treated group 
compared to the control mice (Figure 4-4A).  
 
Tumor dimensions (width, length and height) were obtained using a digital caliper 
to determine tumor volume (mm3). Tumor volume of each mouse was normalized to the 
initial volume before starting EDL-360 treatment (day 0). A slight attenuation of tumor 
growth was observed as early as 3 days post-treatment (P = 0.077) (Figure 4-4B). The 
tumors in the EDL-360 treated mice were significantly smaller compared to control mice 
after 7, 10 and 14 days of treatment (P = 0.03, 0.02, and 0.02 respectively). The 
difference in tumor size between EDL-360 treated tumors and the controls increased with 
time of treatment. For instance, 3 days after treatment the EDL-360 treated tumors were 
1/3 the size of the control group (Mean =1.5 vs 5 normalized tumor volume). After 14 
days of treatment, the treated tumors were 1/6 the size of control group (Mean = 12.5 vs 
74 normalized tumor volume). In addition, non-invasive live imaging was employed to 
evaluate tumor growth in EDL-360 and control mice. Bioluminescence signal showed an  
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Figure 4-4. Intratumoral treatment with EDL-360 in human glioma xenograft 
mouse model. 
 
U87luc cells were injected SQ into the right flank of the mice. Once the tumor become 
palpable the mice were randomly placed in the study. A, Mouse weight was obtained 
twice a week. There was no sign of toxicity or weight loss in EDL-360 treated group 
compared to the control mice. B, Tumor dimensions (width, length and height) were 
obtained using digital caliper to determine tumor volume. The tumors of the control mice 
were growing significantly faster compared to EDL-360 treated mice (P < 0.03). C, 
Bioluminescence signal from control and treated mice showed an obvious decrease in 
tumor viable cells after 17 days of treatment. D, Quantification of bioluminescence 
signals showed a continuous tumor growth in the control mice. In addition, there was a 
significant decrease in tumor growth in the drug treated mice compared to the controls (P 
< 0.03). Bars represent the means; whiskers represent the standard deviation (±); * p < 
0.05. 
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Figure 4-4.  Continued. 
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obvious decrease in tumor viable cells at 17 days of treatment compared to the controls 
(Figure 4-4C). Quantification of photons showed a continuous tumor growth in the 
control mice (Figure 4-4D). In addition, EDL-360 treated tumors had a significantly 
lower growth rate compared to the controls (P < 0.03). 
 
 
Effect of SP-6-27 in Human Glioma Xenograft Mouse Model 
 
SP-6-27 was the most potent chromene analog in glioma cell lines in vitro and its 
activity was assessed in U87luc human glioma xenograft mouse model. Glioma-bearing 
mice were randomly divided into 3 groups. Treated groups received 100 μL daily dose of 
0.2 or 2 μM SP-6-27/0.1% acetic acid, whereas the control group received 100 μL of 
0.1% acetic acid. Mice were monitored daily for any signs or symptoms of drug related 
toxicity. Total body weight, tumor volume, and bioluminescence imaging were obtained 
twice a week during the study period. However, it appeared that the low pH environment 
created by the use of acetic acid affected the bioluminescence signal [172]. Therefore, the 
bioluminescence imaging results were excluded from the study. We observed no signs of 
drug related toxicity in the treated groups. In addition, there was no weight loss in 
SP-6-27 or vehicle treated groups (Figure 4-5). Drug treated groups had a smaller tumor 
volume compared to the vehicle treated group. Mice receiving 2 μM SP-6-27 had 
significantly smaller tumors after 4 and 11 days of treatment (p = 0.016). As expected, 
tumor size decreased in a dose dependent manner. 
 
 
Discussion 
 
The THIQ analog, EDL-155, was found to be the most potent analog in rat 
glioma model [165]. When compared to other anti-cancer agents such as 5-fluorouracil, 
BCNU and melphalan, EDL-155 most effectively induced glioma cell death. In 
agreement with previous studies, EDL-155 was found to be very potent. The IC50 values 
ranged from 6-15 µM depending on the glioma cell line [165]. In the current study, we 
showed that all the THIQ analogs tested were more potent than TMZ, a standard 
chemotherapeutic agents for treating glioma. Interestingly, LN18 cells were resistant to 
the cytotoxic action of TMZ (~390 µM) and in our study EDL-155 was found to be 
highly toxic to LN18 cultures (~ 4 µM) (Figure 4-2B). This could indicate a potential use 
of our THIQ derivatives in combination with TMZ for TMZ-resistant gliomas. Further 
modifications in the A and D rings were made in attempt to improve the toxicity as well 
as the selectivity. The activity was lost in EDL-232 and partially recovered by adding 2 
ortho-methoxy groups in A ring. Consequently, structure activity relationship showed 
that changing the methoxy groups to meta- (EDL-355) and para-position (EDL-358) 
(Figure 4-2E and Figure 4-2F), resulted in an obvious improvement of the cytotoxicity 
(EDL-355) as well as selectivity (EDL-358). Additionally, we lengthened the carbon 
linker between biphenyl and THI ring to 2-carbon atoms (EDL-360), which resulted in a 
further increase in the potency of the compound while maintaining low toxicity in 
astrocytes. However, adding an additional carbon atom (EDL-361) led to decreased in 
the cytotoxicity (Figure 4-2H). In conclusion, in vitro screening suggested that EDL-360 
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Figure 4-5. Intratumoral treatment with SP-6-27 in human glioma xenograft 
mouse model.  
 
The mice were divided in 3 groups, 5 mice/group. Control mice were injected daily with 
0.1% acetic acid and treated groups were injected daily with 0.2 μM or 2 μM SP-6-27 in 
0.1% acetic acid. A, Mice weight was obtained twice a week. There was no sign of 
toxicity or weight loss in SP-6-27 treated group compared to the vehicle control mice. B, 
Tumor dimensions (width, length and height) were obtained using digital caliper to 
determine tumor volume. Tumors in the SP-6-27 treated groups were growing at a slower 
rate compared to the control mice. Mice that received 2 μM SP-6-27 had significantly 
smaller tumors after 4 and 11 days of treatment (p = 0.016). Bars represent the means; 
whiskers represent the standard deviation (±); * p < 0.05. 
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is the most potent THIQ analog. Interestingly, it appears that EDL-360 exhibited a 
selective toxicity in LN18 and A172 cultures when compared to T98 and U87 cultures 
raising the potential of use of this analog in the clinical setting for gliomas that are 
resistant to TMZ.  
 
Chromene analogs were a second group of compounds that were assessed for their 
potency against glioma. Chromenes are analogs of podophyllotoxin, a natural plant 
product, that have been isolated from Podophyllum species [169]. Early clinical trials 
revealed that podophyllotoxins induce cell death by inhibiting microtubule assembly 
[169]. In addition podophyllotoxins can inhibit purine biosynthesis and its incorporation 
into the RNA as well as decreasing the activity of mitochondrial enzymes such as 
cytochrome oxidase and succinoxidase. More importantly, podophyllotoxin derivatives 
are potent inhibitors of DNA topoisomerase II and hence induce cell death [173]. 
Consequently, several studies reported these derivatives as potent anti-cancer agents 
[174-177]. In vitro screening of various chromene analogs revealed that SP-6-25, 
SP-6-35, SP-6-41 and SP-6-43 are the least potent analogs (Figure 4-3). The IC50 of 
these compounds was in micromolar range. However, SP-6-27 followed by SP-6-19 were 
the most potent chromene analogs tested in the current study. More importantly, these 
compounds demonstrated very low activity in normal astrocytes compared to glioma cell 
lines, implying a potential benefit with least toxicity. Based on structure activity 
relationship, it appears that the substitution of electron withdrawal atom on D-ring and/or 
electron donor atom on C-ring resulted in an improvement of chromene potency [168].  
 
Based on our in vitro drug screening findings, we selected the most potent THIQ 
(EDL-360) and chromene (SP-6-27) analogs for in vivo evaluation in human glioma 
xenograft model to address this question. EDL-360 caused partial regression in tumor 
size (Figure 4-4B) without causing a notable toxicity in the treated mice (Figure 4-4A). 
Tumor size was determined by digital caliper measurement and live animal 
bioluminescence imaging (Figure 4-4C and Figure 4-4D). However, it is still unclear 
whether EDL-360 could penetrate the BBB, and would exert a similar anti-cancer effect 
when the tumors were grown intracranially. Previous studies showed that EDL-155 could 
penetrate the BBB, with 1.4% brain to plasma exposure ratio [178]. However, it is not 
possible to expect that EDL-360 would exhibit good penetrance across the BBB as well. 
Slight variation in the chemical structure could lead to great changes in the biological 
responses. Similarly, tumor-bearing mice that were treated with SP-6-27 did not lose 
weight or showed signs of toxicity (Figure 4-5A). Additionally, SP-6-27 treatment 
caused a partial regression in tumor size (Figure 4-5B) similar to EDL-360 treated 
tumors. However, treatment with the vehicle (acetic acid) resulted in in a slight decrease 
in tumor growth, which in part could mask the effect of SP-6-27. In conclusion, 
EDL-360 and SP-6-27 have potential as anti-cancer agents. However, the limited 
solubility of SP-6-27 in aqueous solutions may be a limiting factor. Further investigations 
are required to test the anti-cancer activity of these small molecules in pre-clinical glioma 
mouse models. 
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CHAPTER 5.    DISCUSSION AND CONCLUDING REMARKS 
 
 
 Over the past 10 years, despite improvement in diagnosis and therapies for cancer, 
the survival rate for high-grade glioma patients remains low. In the current study, we 
investigated the effects of corticosteroids and thiopurines in the brain because they have 
been associated with increased resistance to chemotherapy or gliomagenesis, 
respectively. 
 
 
Corticosteroids Might Reduce the Efficacy of Chemotherapy and Radiotherapy 
 
Vasogenic edema develops in aggressive gliomas and corticosteroids are the first 
clinician choice to alleviate the neurological symptoms [9,72]. Despite the intensive use 
of Dex in the clinic, its effect on glioma  is not precisely identified. Whether Dex has 
anti-proliferative or anti-neoplastic properties, or whether it stimulates cell growth has 
been a long debate in the literature [35,36,76,77]. We have found that Dex treatment 
decreases tumor cell proliferation as shown by PCNA and Ki67 IHC staining and hence it 
exhibits an anti-proliferative effect. Since cancer therapeutics often target rapidly 
growing cells, it is quite possible that Dex might compromise the responsiveness of 
tumor cells to chemotherapy and/or radiotherapy via inhibiting tumor cell growth. 
Indeed, several studies suggested that Dex might compromise the responsiveness of 
tumor cells to chemotherapy and/or radiotherapy[37,92,93]. Pre-treatment with Dex 
induces Bcl-xL expression and inhibited cell death induced by staurosporine, 
camptothecin and etoposide in astrocytoma cultures [93]. In breast and ovarian xenograft 
animal model, pretreatment with 1 mg/kg of Dexwas found to reduce the anti-cancer 
action of paclitaxel by 20-25% [179]. Such findings highlight the desperate need to 
understand the exact effect of Dex on tumor cells especially for patients undergoing 
chemotherapy or radiotherapy concurrently with corticosteroids, and raises the concern 
that Dex treatment should not be combined with DNA damaging agents such as 
chemo- and radio-therapy.  
 
 
Corticosteroids Decrease Microglial Cell Number and M2-Like Microglial Cells 
 
The mechanism of how Dex alleviates cerebral edema is mostly unknown. 
However, it has been proposed that Dex might improve peritumoral edema through its 
anti-inflammatory effect or by inhibiting microglial cells proliferation and 
pro-inflammatory cytokine production [68,73]. In rat glioma, DEX was found to decrease 
microglial cell proliferations infiltration into the tumor [73]. In the current study, we 
found that Dex decreases microglial cell content in tumor sections as confirmed by 
anti-Iba-1 primary antibody in PDGF driven glioma mouse model. (Figure 2-6A). 
However, two different phenotypes of microglial cells exists; M1 and M2. M1-like 
microglial cells are known to possess pro-inflammatory properties. In contrast, various 
studies suggested that tumor-associated microglia could support the tumor proliferation 
and growth, and possess an M2-like anti-inflammatory phenotype [78,97,98]. In 
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agreement with previous findings, we found that tumor associated microglia exhibit an 
M2-phenotype in a PDGF induced-glioma model (Figure 2-7). This implies that 
inflammatory microglial cells may not play a major role in edema formation, and Dex 
might alleviate peritumoral edema by a mechanism other than inhibiting the 
M1-pro-inflammatory microglial cells.  
 
 Several studies found a decrease in the production of several pro-inflammatory 
cytokines such as COX2, NO, IFNγ and TNFα in lipopolysaccharide induced upon Dex 
treatment [180-182]. However, lipopolysaccharide induces the classical activation of 
microglial cells to M1-pro-inflammatory phenotype and it is well defined that microglial 
cell exhibit M2-pro-tumor phenotype in tumor microenvironment [78,86]. To our 
knowledge, this is the first study that investigates the effect of Dex on the gene 
expression of M2-like microglial cells using a clinically relevant glioma model. We 
found a shift in the microglia phenotype towards less M2 (MMP9 and IL-1ra) in both in 
vitro and in vivo samples upon Dex treatment. MMP9 is a member of matrix 
metalloproteinases family, which is produced primarily by immune cells such as 
macrophages/microglias and neutrophils [101]. MMP9 plays a pivotal role in tumor 
progression and invasion [97]. MMP9 deficient mice have less lung metastases in both 
melanoma and lung carcinoma animal models [102]. More importantly, MMP9 plays an 
important role in angiogenesis and induction of cell proliferation [101,103,104]. It is 
plausible that targeting M2-microglial cells could have a potential therapeutic benefit for 
treating glioma [183]. However, the use of corticosteroids in managing glioma is 
problematic, since it is associated with a decreased response to anti-cancer therapy.  
Consequently, we addressed the question of whether this decrease in M2-pro-tumor 
phenotype could play a role in tumor cell proliferation in Dex treated samples. Therefore, 
we investigated the anti-proliferative effect of Dex using primary glioma cultures. In 
contrast to our in vivo results, we could not detect a cell proliferation inhibition following 
Dex treatment. These contradicting findings highlight the difference between in vitro and 
in vivo conditions and this does not eliminate the possibility that microglial cell play an 
important role in supporting tumor cell proliferation.  
 
Taken together, Dex might act against glioma favorable conditions in our mouse 
model. However, this effect might or might not be recapitulated when Dex is combined 
with DNA damaging agents such as ionizing radiation. Finally, the current study 
highlights the urgent need to find better therapeutic alternatives to corticosteroids that 
have less adverse effects and interfere less with anti-cancer therapy. Further studies 
should focus on identifying the mechanism of action by which Dex inhibits cell 
proliferation. In addition it is important to investigate whether Dex alleviates preitumoral 
edema by inhibiting the expression of VEGF and hence decreases the permeability of the 
BBB. 
 
 
Low TPMT Activity Leads to Increases in TG-Induced Toxicity 
 
Thiopurine drugs are commonly used in the treatment of cancer, autoimmune 
disorders, and transplantation. TPMT is a cytoplasmic enzyme that deactivates thiopurine 
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drugs and a low TPMT phenotype can lead to life-threatening hematological toxicities 
when standard doses of thiopurines are given. The use of these agents has been linked 
with the development of secondary brain tumors in TPMT-deficient patients [42,47]. 
Astrocytomas are the most common brain tumor type that has been reported in patients 
after thiopurine therapy [47,48,50,67]. Unfortunately, not all patient populations that are 
treated with thiopurines are evaluated for their TPMT status prior to initiating thiopurine 
therapy; hence, the importance of TPMT to thiopurine-associated cancer risk is not clear. 
Since TPMT deficiency is relatively rare across populations, it is difficult to assess the 
importance of TPMT status to thiopurine therapy-related cancer risk. However, in a 
report by Relling et al. it was shown that whether patients developed a brain tumor as a 
late complication of post-antileukemic therapy depended on their TPMT status [47]. 
Patients who were determined to be at high risk for treatment relapse received 
prophylactic cranial irradiation concurrent with antimetabolite therapy; and those patients 
with a low TPMT had a surprisingly high incidence of brain tumors as a late 
complication. Indeed, ionizing radiation is a risk factor for brain tumorigenesis. However, 
in this report, patients with low TPMT had a 42.9% incidence of brain tumors compared 
to 15.8% for those with high TPMT. To our knowledge, the importance of TPMT status 
to thiopurine-associated phenotypes in the brain has not been investigated. 
 
We found that low TPMT phenotype was associated with significantly higher 
sensitivity to thiopurine than a high TPMT phenotype. In agreement with previous 
studies, we found that thiopurines induced significantly more cell death and DNA 
damage (SSB and DSB) [156]. Interestingly, we found that low but not the complete 
absence of TPMT sensitized primary astrocytes to a higher degree of cytotoxicity and 
genotoxicity (i.e. IC50, SSBs and DSBs) after TG exposure. These results suggested that 
heterozygosity in TPMT may lead to the greatest genotoxic effects of thiopurine therapy. 
In part this could be explained by the induction of compensatory mechanism that 
deactivates thiopurines upon the complete loss of TPMT. The loss of TPMT could have 
led to the overexpression of xanthine oxidase, which deactivates thiopurine agents to 
thiouric acid. Interestingly, some studies suggest that children with TPMT heterozygosity 
develop brain tumors and other cancers more frequently than children with mutant TPMT 
[164]. Another possible explanation could be a defect in the mismatch repair (MMR) 
system's ability to recognize DNA-TG nucleotide lesions in TPMT mutant cultures. The 
MMR system is responsible for recognizing DNA mis-pairing caused by DNA-TG 
nucleotides and the subsequent signaling for cell death [160-163]. The latter possibility 
suggests that astroglial cells with a defective TPMT activity could have DNA lesions 
persisting in the genome that could potentially lead to mutagenesis and cancer. However, 
the frequency of heterozygous or mutant TPMT is very low making it is difficult to make 
any definitive conclusions [47,164]. Indeed the current study raises the concern about 
thiopurine toxicity not only in TPMT mutant individuals but also in TPMT heterozygous. 
Therefore, a routine assessment of TPMT activity might be required for patients 
receiving thiopurine agents.  
 
In summary, chronic thiopurine therapy has been associated with the development 
of brain cancer and TPMT status has been linked to brain tumor risk. We found that 
TPMT is an important factor for thiopurine drug-induced cytotoxicity and genotoxicity in 
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astroglial cells. Because of the limited availability of human astrocytes we used human 
glioma cell lines. Although glioma cells can exhibit a number of genetic alternations that 
could contribute to the phenotypes observed, our study shows that TPMT is indeed an 
important determinant of thiopurine toxicity. The observation that glioma cells can have 
variable degrees of TPMT protein activity and that low protein activity can cause cells to 
be more sensitive to TG may suggest that thiopurines may potentially have a therapeutic 
role in low TPMT expressing glial tumors. However, since thiopurine drugs are linked 
with secondary brain tumors, we do not recommend the use of these agents in brain 
tumor treatment. Furthermore, In vitro studies have shown that thiopurine drugs are 
associated with mutagenic events in a variety of cell lines [116,151]. 
 
Further studies are needed to understand the importance of TPMT in the brain 
when thiopurines are given. Whether these findings can be replicated in vivo and whether 
factors important to DNA repair mechanisms are responsible for the TG phenotypes 
described in this study should also be investigated. Finally, It would be interesting to 
investigate whether TPMT status influences the extent of TG nucleotide incorporation 
into DNA and damage recognition by the MMR system as well as whether ionizing 
irradiation alone or in combination with thiopurines results in similar findings.  
 
 
EDL-360 and SP-6-27 Exhibit Anti-Glioma Activity In Vitro and In Vivo 
 
Despite aggressive therapeutic approaches to treat glioma, there is no significant 
improvement in either the prognosis or the survival of patients. Therefore, there is an 
urgent need to find new therapeutic approaches to improve patients’ survival and 
outcome. The current study focused on assessing the potential anti-cancer activity of two 
categories of small molecules; THIQ and chromenes.  
 
The anti-cancer activity of our compounds has been tested in vitro using MTT cell 
viability assays. Since glioma is a heterogeneous tumor, the in vitro drug screening was 
performed in four human glioma cell lines (T98, U87, LN18 and A172). Although 
normal human astrocyte cultures may be more appropriate as a model of normal brain 
cells, normal murine astrocyte cultures were used due to their availability in our 
laboratory. Based on our in vitro screening, we identified EDL-360 and SP-6-27 as the 
most potent derivatives with lowest toxicity to normal stromal cells. Interestingly, it 
appears that EDL-360 exhibited a selective toxicity in LN18 and A172 cells when 
compared to T98 and U87 cells raising the potential use of this analog in the clinical 
setting for gliomas that are resistant to TMZ. SP-6-27 exhibits cytotoxicity in nanomolar 
range (IC50 = 7-21 nM). Tubulin polymerization inhibition could in part play a role in 
SP-6-27 induced toxicity [168]. However, inhibition of tubulin polymerization by 
SP-6-27 was weak and other mechanism of actions might play a major role in SP-6-27 
induced toxicity. 
 
The anti-cancer activity of EDL-360 or SP-6-27 was further tested in 
glioma-bearing mice generated by injecting human glioma U87luc cells subcutaneously in 
immunocompromised mice. Despite the fact that U87 cell produces glioma characterized 
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by leaky BBB similar to human glioma, the tumor does not have infiltrative nature [19]. 
There was no sign of toxicity as indicated by the absence of weight loss in the treated 
groups (EDL-360 and SP-6-27) compared to the control mice. The tumors of EDL-360 
treated mice were significantly smaller compared to control mice after. In contrast 
SP-6-27 treatment resulted in a partial regression of tumor size. However, it is still 
unclear whether EDL-360 or SP-6-27 could penetrate the BBB and exerts a similar 
toxicity when the tumors grown intracranially. Previous studies showed that EDL-155 
(THIQ analog) could penetrate the BBB, with 1.4% brain to plasma exposure ratio [178]. 
However, it is possible to expect that EDL-360 would exhibit better penetration of the 
BBB since it is a methoxy rather that a penolic substituted compound. Slight variation in 
the chemical structure could lead to great changes in the biological responses. Similarly, 
SP-6-27 treatment caused a partial regression in tumor size. However, acetic acid treated 
tumors did not grow as fast as non-treated tumors and this in part masking the effect of 
SP-6-27. It is also plausible that the stromal cells provide growth support to the tumor 
cells, rendering SP-6-27 ineffective.  
 
In conclusion, EDL-360 and SP-6-27 have potential as anti-cancer agents. 
However, the limited solubility of SP-6-27 in aqueous solutions could be a limiting factor 
for its use. The synthesis of the corresponding sodium or phosphate salts of SP-6-27 may 
enhance its water solubility. Probing the structure activity relationship of EDL-360 may 
improve its anti-cancer activity. In addition, further investigations are required to test the 
anti-cancer activity of these small molecules in an intracranial xenograft model, which 
would allow tumor development in the native microenvironment of the brain, and thus 
allows more reliable assessment of anti-glioma novel therapies. 
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